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Abstract 
Screening mammography is the gold standard for early breast cancer detection 
and a cornerstone of preventive medicine. Traditional mammography is currently 
being replaced by newer, more eloquent digital technology. Clinical trials have 
not proven that digital mammography reduces breast cancer mortality or burden 
of suffering. Nevertheless, the technology has spread according to Everett 
Roger's "Diffusion of Innovation" pattern. The purpose of this Master's Paper is 
closely to examine the process by which breast cancer screening in the United 
States has evolved from screen film mammography to full-field digital 
mammography. This is a qualitative, iterative analysis that triangulates analyses 
of the medical literature, elite interview responses, and media coverage to 
cultivate a storyline about the development and dissemination of digital 
mammography. The technology has spread because of our national hunger for 
computers and innovation, our eagerness to support the "war on cancer," public 
perceptions about the technology's theoretical advantages, and ongoing efforts 
of advocacy groups to maintain health care equality. Although digital 
mammography is significantly more expensive than is screen film mammography, 
cost-effectiveness considerations have been deferred by many health care 
leaders. Regulating technologies such as digital mammography, which are 
extremely expensive but do not confer better public health outcomes, is a 
necessary component of fixing our health care system. 
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Preface 
This paper is meant to be a critical analysis, written from the perspective of a 
student of public health, medical literature, public policy, and social change. 
chose a topic about which I am passionate, which is cancer prevention, 
screening, and mammography. I chose to examine digital mammography 
because, when I began the work, I did not have a strong, predefined opinion 
about whether this is the appropriate direction for breast cancer screening. The 
reader should know my hypothesis when I began this project: The adoption and 
dissemination of digital mammography has followed a trajectory similar to that of 
other medical technologies in the United States. That is, digital screening 
mammography has not been introduced to the health care system in a 
systematic, synchronized, or evidence-based manner. Rather, leaders and 
groups with vested interests in the success of digital mammography have been 
most significant in the technology's disorganized development and introduction. 
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Introduction 
.. . this has sort of been an interesting issue around evidence-based medicine. 
It's sort of what happens, and particularly in an environment where you have a 
strong, significant advocacy group ... the public has driven this, and it sort of went 
right by where the evidence was. 
-- Carl Ravin, MD, Chairman, Department of Radiology, Duke University Medical 
Center (DUMC) 
In September 2007, the University of North Carolina at Chapel Hill (UNC) 
became the first hospital in North Carolina to transition completely from screen 
film to all-digital mammography. These two screening modalities both use X-rays 
to obtain breast images. Screen film images are captured on film, but digital 
images are deposited in computer software. Thus, digital images may be 
manipulated to adjust contrast, brightness, or magnification. We have been 
eager to implement digital mammography because of its potential to improve the 
diagnostic accuracy of traditional, screen film mammography. This potential, if 
realized, would be enormously positive for the fields of preventive medicine and 
oncology. 
Many of our current medical technologies were also introduced into the health 
care system because of their potential to improve public health. Unfortunately, 
too many of these have turned out to be extremely expensive without contributing 
significantly to improved clinical outcomes. The medical profession has recently, 
however, become more attuned to using evidence as a guide for individual 
practices, and a method for improving both effectiveness and cost-effectiveness 
of interventions. In the case of digital mammography, several large clinical trials 
have compared the technology with screen film mammography. Overall, these 
trials have not demonstrated considerable diagnostic advantage of digital 
screening for the majority of the population. Nevertheless, as Dr. Ravin said, we 
have gone "right by where the evidence was." 
The purpose of this analysis is to conduct a critical examination of digital 
mammography by identifying the variables most likely to explain its emergence 
and rapid adoption. Popular culture encourages Americans to buy the most 
expensive and innovative things on the market, whether they are electronics, 
automobiles, or health care devices. Doctors may choose to adopt uncertainly 
supported practices because of available resources, personal experiences, or 
even political loyalties. At the health system level, adoption of new technologies 
is fragmented because separate parties are responsible for developing, 
approving, funding, marketing, and distributing products. In this disorganized 
process, no one has the advantage of a completely balanced, "big picture" 
understanding of new medical interventions. Moreover, no entity has the 
authority to regulate technologies using this "big picture." 
Above and beyond these baseline forces that seem to impel the adoption of 
technology, digital screening mammography has been introduced into the system 
against a backdrop of ongoing national discussions about breast cancer 
screening and prevention. Participants in this discussion include government 
organizations, cancer and women's advocacy groups, innovators of digital 
technology, breast imaging specialists, private vendors of digital equipment, and 
third-party payers. All these interests have had stakes in digital technology's 
dissemination. In this complex process, the evidence has been muffled, 
manipulated, misunderstood, and even completely forgotten by both groups and 
health care leaders. 
Nowhere can these various perspectives be better explored than through 
interviews with elite stakeholders and analyses of media coverage of digital 
mammography. Therefore, this qualitative analysis is iterative, relying on a 
triangulation of analyses of medical literature, respondent interviews, and media 
accounts to draw conclusions about influences on the adoption of digital 
screening mammography. The fruit of this triangulated analysis is a storyline of 
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digital mammography, which provides one account of its development and 
introduction. 
Prior to beginning the story of digital screening mammography, we need to make 
clear two major limitations on this type of study. First, the study relies on a 
modest amount of data from which to extract relationships and draw conclusions. 
To compensate for the small sample size, I have collected information from elites 
with different perspectives in health care and unique areas of expertise. The 
media analyses are based on a review of articles from the nation's major 
newspapers. Second, qualitative and iterative research cannot be used as a 
vehicle to prove causation. Although this analysis is presented in a stepwise 
fashion, the data cannot support any one action/event directly causing another. 
One of the purposes of triangulating methods, however, is to collect data from 
multiple sources and impute strong relationships between interests and events. 
To the degree that different methods converge on a single answer, the methods 
have provided some cross-validation of one another, and the answer is likely to 
be more robust. 
3 
Qualitative Methods: Elite Interviewing and Newspaper Analyses 
Two standard methods of gathering social science data are through analyses of 
interviews and documents.1-3 I extracted data from interviews and newspaper 
articles using a dynamic analytical process in which I generated, tested, and 
refined hypotheses about the most significant social factors affecting the 
adoption and dissemination of digital mammography. I used the well-recognized 
social research process of coding to both develop and support hypotheses from 
my field work2 · 3 I acquired skill in document coding through intensive training at 
the Odum Institute for Research in Social Science (University of North Carolina 
at Chapel Hill)3 and by reading three reference books about qualitative research: 
Bogdan's Introduction to Qualitative Research Methods, Bailey's Methods of 
Social Research, and Berg's Qualitative Research Methods for the Social 
Sciences. 1• 2· 4 
Briefly, I coded both interview responses and newspaper articles using the 
following parameters: (1) most important topics, as determined by length of 
interview discussion or word counts in newspaper articles, (2) areas of apparent 
consensus, for example agreement among interviewed radiologists about the 
similar subjective experience of women receiving a digital versus film 
mammogram, and (3) areas of disagreement or contradiction, such as different 
opinions about the role scientific evidence in the adoption of digital 
mammography. I also coded each newspaper article according to its publication 
date, words used in the title, key words and/or phrases used in the article's text, 
presence of medical evidence citations, and overall tone of the article. 
Summaries of the coding schema for the interviews and newspaper articles are 
found in Appendices 1 & 2. Ideally, the codes I developed for data extraction 
should be reviewed and verified by another social science researcher to bolster 
their validity and reliability. Due to limited resources and time constraints, 
however, no second coder was able to review my data at the time of this writing. 
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The purpose of interviewing elite stakeholders is to gather information and 
perspectives that cannot be obtained from surveys or other public documents. 
Elite interviewing focuses on how leaders frame their views and how they make 
connections or reveal disjunctions between their opinions. In her work with elite 
interviewing, Hochschild says the purpose of such interviews is to contextualize 
issues from the perspectives of those involved in shaping them. 5 In the case of 
mammography, elite interviewing is appropriate because leaders from various 
fields have essentially spearheaded the national push for digital screening in the 
absence of mandates compelling such a transition. Understanding their views of 
the process is, in significant ways, to understand the process itself. 
Over the course of one month, I conducted a total of ten interviews with twelve 
elites in the fields of radiology, breast cancer screening, hospital administration, 
and public policy. I received permission from UNC's Institutional Review Board 
(IRB) to conduct these interviews, and obtained verbal consent from each 
participant to record, transcribe, and include their responses in my analysis. 
transcribed all interviews, which varied in length between 15 and 45 minutes, in 
the "naturalist" style including notations of pauses, incomplete statements, and 
other non-verbal communication. The IRB-approved interview questions and a 
list of respondents are located in Appendices 3 & 4. 
The media have always been a powerful agenda-setter in our country. John 
Kingdon, in his classic work Agendas, Alternatives, and Public Policy, found the 
media have a significant role in magnifying issues.6 In theory, professional 
journalists maintain a "wall of separation" between news pages and editorial 
pages. Often, however, the media report in ways that actually shape and 
structure issues.6• 7 Kahn and colleagues analyzed breaches in the "wall" and 
found that newspaper reporting is affected by the political views of editors, who 
alter the tone of the news coverage about incumbents.7 In the case of digital 
mammography, the media likely served two purposes: spreading information 
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about digital technology to the public and framing the public's perception of the 
technology. 
My media search included the top twenty-five circulating United States 
newspapers, according to A. C. Nielsen's spring 2007 assessment (Appendix 5). 
Although newspaper readership among the U.S. lay public has declined with our 
increased preference for television and internet news, policy makers and medical 
elites continue to read and contribute to newspaper articles. Also, the results of 
newspaper searches are very reliable indicators of media coverage, since the 
choice of stories in other media is reflected, and often even stimulated by, what 
newspapers choose to cover. 
I accessed the majority of newspapers electronically through the UNC Libraries 
website; however, USA Today, The Wall Street Journal, and The L.A. Times 
were not directly available through the website. I used LexisNexis® to access 
USA Today articles and Procite® to access The Wall Street Journal and The L.A. 
Times. I searched each newspaper database using key terms "digital 
mammography" and excluded reprints, brief financial statements, articles that did 
not contain the words "digital mammography" together in context, and articles 
that only mentioned digital mammography as a peripheral subject (ie. in 
obituaries or biographies). The initial media search yielded 500 articles, of which 
215 met inclusion criteria. 
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Weighing the Evidence: Review of the Medical Literature 
Approach to Reviewing the Literature 
The strongest evidence-based approach to evaluating digital mammography 
would involve answering the following question: "Does digital mammography 
screening decrease breast cancer mortality rates more than does screen film 
mammography?" This fundamental question of comparative effectiveness 
should be addressed prior to adopting any new screening tool. In addition, it is 
critical to review the literature regarding relative harms and costs of digital as 
compared to film mammography. This chapter addresses both the comparative 
effectiveness and cost-effectiveness of digital mammography. A subsequent 
chapter, entitled Perceptions with Real Consequences, investigates the potential 
hazards of adopting digital mammography as the standard breast cancer 
screening method. 
The purpose of any screening test is not simply to detect disease, but to help 
people Jive longer Jives with higher quality because they are treated for the 
disease intended to be detected at an early stage by screening. Thus, screening 
tests are only effective if they detect diseases that can be successfully treated. 
In the case of digital mammography, researchers have conducted randomized 
and paired-comparison trials to study the diagnostic accuracy of digital versus 
film screening for breast cancer lesions. These types of studies are necessary to 
ensure that digital mammography does not miss breast cancers that would have 
been detected by screen film mammography. The inherent problem with these 
studies, however, is that they cannot demonstrate which modality is a more 
effective screen for relevant breast cancers, or those that can be treated to 
enable women live longer lives with less morbidity. 
In general, screening examinations are more likely to detect indolent forms of any 
disease because of length-biased sampling. In other words, patients with less 
lethal forms of disease are more likely to be identified on screening exams 
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because they remain in the pre-symptomatic, screening-detectable phase of 
disease for a longer time. The natural history of indolent breast cancers, such as 
low-grade ductal carcinoma in situ (DC IS), is variable. Although digital 
mammography may enable more breast cancer diagnoses, these diagnoses 
could include a significant number of indolent breast cancers. These cancers 
may be detected earlier on full-field digital mammography, but could have been 
detected later on film mammography with no change in clinical outcome for the 
woman. Alternatively, many digitally detected breast cancers may never have 
become clinically apparent. Women with these sub-clinical cancers may be 
exposed to painful and unnecessary treatments, such as surgery and 
chemoradiation. In scenarios such as this, digital screening mammography does 
not serve its intended purpose of helping women live longer and/or more 
healthfully. 
The best way to evaluate the value of digital versus film mammography for breast 
cancer screening would involve a randomized controlled trial (RCT). The 
investigators should randomize women to receive either digital or film 
mammography, and follow them over years (or even decades) to determine 
which group experienced lower breast cancer mortality rates and also which 
group had the greatest number of false positive and/or negative screens. 
Although having data from such an RCT would be ideal from the perspective of 
evidence-based medicine, designing the trial would be difficult for several 
reasons. First, the relationship between screen film mammography and 
decreased breast cancer mortality is already well-documented in the literature. 
Restarting mortality trials with the digital "upgrade" would require tremendous 
funding and other resources to monitor patients over time. 
In addition, any relationship between breast cancer screening and mortality is 
undercut by advances in cancer therapy. Because cancer therapy will improve 
alongside any trial to compare screening modalities, it would be difficult to 
distinguish between the effects of digital screening and the effects of more 
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sophisticated therapies on breast cancer mortality. To explore this phenomenon, 
Berry and associates used mathematical models to estimate the distinct effects 
of screening, chemotherapy, and tamoxifen on breast cancer mortality reduction 
since 19758 The models provide estimates of how much mortality reduction is 
attributable to cancer screening versus therapy. The models attribute breast 
cancer screening with reducing breast cancer mortality by a range of 7.5% to 
22.7%, with a median value 15.3%, over the past 25 years. The proportion of the 
overall decreased breast cancer mortality attributable to screening, as compared 
to chemotherapy and/or tamoxifen, ranged between 28% and 65% with a median 
value of 46% since 1990. 
As becomes clear, systematically reviewing the literature for effectiveness 
evidence about digital screening mammography is complicated by several factors. 
Studies examining the influence of digital screening on mortality are not available, 
and studies examining the accuracy of digital screening are subject to length-
time bias. Despite these limitations, I proceeded with a systematic literature 
review to answer the following question: "Among women seeking breast cancer 
screening, does digital mammography have greater diagnostic accuracy than film 
mammography?" Studies which evaluate the diagnostic accuracy of digital and 
screen film mammography must be rigorously analyzed for high-quality, 
transparent reporting of methods and results as outlined in the Standards for 
Reporting of Diagnostic Accuracy (STARD) criteria 9 Thus, I only reviewed 
articles that included calculations of sensitivity/specificity of the screening tests, 
described the study population and participant recruitment, outlined the data 
collection process, explained the expertise of radiologists reading mammograms, 
and explicitly reported statistical methods. 
Systematic Review 
I searched MEDLINE for trials published over the last ten years, using the MeSH 
term "mammography" and keyword "digital," with the limits of English, Humans, 
Women, Clinical Trial, Randomized Controlled Trial, Comparative Study, and 
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Controlled Clinical Trial. This initial search yielded 103 articles. I only reviewed 
studies of asymptomatic women undergoing breast cancer screening. The study 
interventions were full-field digital mammograms, the comparisons were screen-
film mammograms, and the outcome of interest was breast cancer detection. For 
purposes of this review, breast cancer includes both DC IS and invasive disease. 
Because my focus is on the real-world effectiveness of digital mammography as 
a tool to improve breast cancer outcomes in the population, I specifically 
excluded studies that considered breast tissue calcification(s) a "positive" 
screening test, because detection of only breast macro- and micro-calcifications 
is often an ambiguous indicator for a breast neoplasm. I also excluded studies 
using biopsy specimens or phantom images for comparison between digital and 
film modalities, and studies that relied primarily on computer-aided detection 
(CAD) devices for diagnosis or computed radiography (CR) systems for image 
acquisition. 
Four major studies met these inclusion/exclusion criteria: (1) Lewin and 
associates' 2001 comparison of full-field digital and screen film mammography, 
(2) the Oslo I Study, (3) the Oslo II Study, and (4) the Digital Mammographic 
Imaging Study (DMIST). An abbreviated summary of each trial's design and 
major findings is located in Appendix 6. 
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Figure 1: Summary of Clinical Screening Trials Comparing Film and Digital 
Mammography 
Statistically significant findings appear in bold 
Trial Lewin and Oslo I Oslo II: Ages Oslo II: DMIST: 
colleagues 45-49 Ages 50- All ages 
69 
Study Design Paired- Paired- RCT RCT Paired-
comparison trial comparison comparison 
trial trial 
Ages Included >40yo 50-69 45-69 50-69 All 
Sites 2 1 1 1 33 
Number of 6,736 exams in 3,683 Film: 7,607 Film: Film: 42,745 
exams 4,489 women Digital: 3,012 10,304 Digital: 
(1 ,665 enrolled Digital: 42,570 
once, 291 3,985 
enrolled twice) 
*Repeat exams 
separated by 
>11 months 
Cancer Film: 0.49% Film: 0.76% Film: 0.22% Film: Film: 040% 
Detection Rate Digital: 0.37% Digital: Digital: 0.27% 0.54% Digital: 
p>.01 0.62% p=0.686 Digital: 043% 
P=0.23 0.83% 
p=0.53 
PPV* Film: 3.3% Film: 21.9% Film: 74% Film: Film: 5%*** 
Digital: 34% Digital: Digital: 7.1% 22.1% Digital: 5%*** 
p>.30 13.7% p>.05 Digital: 
21.6% 
p>.05 
Recall Rate** Film: Film: 3.5% Film: 3.0% Film: 8.4%*** 
14.9% Digital: 4.6% Digital: 3.7% 2.5% 
Digital: p=0.21 p>.05 Digital: 
11.8% 3.8% 
P<.001 p<.05 
Overall Conclusions Lack of Randomization Although 
Conclusions limited because statistically improves high external 
of high number significant internal validity validity, study 
of lesions results and of the study; was limited 
examined with limitations to however, by non-
both screening external overall lack of significant 
modalities validity significant findings and 
reduce findings low internal 
applicability validity 
of study 
Quality (Good, Fair/Poor Fair Fair Fair Fair 
fair, poor) 
*Percentage of abnormal mammograms leading to breast cancer d1agnos1s (by one reader) 
**Recall after consensus meeting, based on abnormal mammographic findings 
***Values were extrapolated from data presented by DMIST authors 
DMIST: 
Age <50 
Paired-
comparison 
trial 
<50 
33 
Film: 14,355 
Digital: 14,355 
Film: 0.22% 
Digital: 0.33% 
p<.003 
Film: 2%*** 
Digital: 3%*** 
10%*** 
Suggests truly 
higher 
sensitivity of 
digital 
mammography 
in one 
subgroup of 
women 
Fair 
II 
Lewin and associates, 2001:10• 11This was the first large study comparing the 
effectiveness of film versus digital mammography for screening purposes. 
Women over forty years who presented at one of two mammography centers 
were included, for a total of 6,736 paired examinations of film and digital 
mammography. Overall, the study found no significant difference between the 
modalities in terms of cancer detection rates or positive predictive values (PPVs). 
The authors did not design this analysis for hypothesis generation, and could not 
conduct statistically meaningful subgroup analyses to compare accuracies of 
each modality among different age groups. 
The major, statistically significant result discussed in this study was lower recall 
rates for patients receiving digital (11.8%) than for patients who had had film 
mammography (14.9%). The authors attributed these lower recall rates to fewer 
false positive results with digital mammography. Interpreting radiologists were 
not masked, though, and could therefore have been more meticulous about 
recalling film than digital cases. 
The primary threat to the validity of this study was the mammography image 
interpretation process. One radiologist read each film, but (s)he was permitted to 
use previous screen film mammograms for comparison. Thus, radiologists could 
have introduced interpretation bias as they based their diagnoses on previous 
images. In addition, many indeterminate cases emerged during the study as 
radiologists found suspicious lesions on one imaging modality but not the other. 
Radiologists discussed these discordant findings at "discrepancy conferences," 
where teams used both digital and film images to make a final diagnosis. These 
indeterminate cases comprised over half the total abnormal findings in the study, 
but were counted as either digital-detected or film-detected lesions for analysis. 
This is problematic because the high volume of cross-reading diluted the actual 
distinction between diagnostic performances of each screening modality. 
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Oslo 1:12 The Oslo I trial, conducted by Skaane and associates, was published 
two years after the study by Lewin and colleagues. Oslo I took place at one site, 
and was designed as a paired-comparison study with 3,683 women aged 50-69 
years receiving both film and digital mammograms. The study found no 
significant difference in the two modalities' rates of cancer detection, PPV, or 
recall. Since the Oslo I did not include women in their forties, the trial's findings 
are not applicable to this subgroup of women. 
Despite not finding significant differences, the Oslo authors did improve upon the 
experimental design of Lewin's study. Each image was reviewed by two 
independent radiologists, who were not given previous screen film images for 
comparison. The radiologists discussed indeterminate breast lesions in teams, 
but the teams were only allowed to use original images to make final diagnoses. 
Oslo 11:13 The main differences between the Oslo I and II studies were that Oslo 
II had a larger study population of 25,263 women, it included women aged 45-49 
years, and it randomized participants to either film or digital mammography. The 
authors found no overall, significant difference in cancer detection rate or PPV 
between screening modalities. Notably, both Oslo I and II found higher recall 
rates for digital mammography than for screen film mammography. These 
results reached statistical significance in the Oslo II study. The higher recall rate 
for digital imaging is the obverse of the trial results by Lewin and associates, who 
found a significantly lower recall rate for digital mammography. This difference 
may be partially attributable to more frequent mammography recalls in the United 
States as compared to Europe. 14 
Although Oslo II was a randomized trial, it has some limitations in its design and 
external validity. First, the soundness of randomization cannot be determined for 
this study, as the authors do not give detailed information about their methods of 
randomization, masking, or concealment of allocation. Also, only Norwegian 
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women participated in both Oslo studies. This population is more homogeneous 
than the population in the United States, where women of different races, 
ethnicities, and even socio-economic classes have distinct screening patterns 
and presentations of disease. Finally, the Oslo studies only used one type of 
digital machine (General Electric's Senographe 20000®). The authors therefore 
could not explore different manufacturers, which may influence cancer detection 
rates. 
One major contribution from both Oslo studies was the documentation of cancer 
types detected by each screening modality. This information is important, as 
histopathology of cancer estimates of the cancer's clinical aggressiveness. 
Histopathology can serve as an intermediate outcome, or marker for cancer 
mortality. Unfortunately, the Oslo I study only detected 31 malignancies, so the 
authors could not draw any significant conclusions about the diagnostic 
performance of either screening modality. A total of 120 cancers were detected 
during the Oslo II study; however, the study was not powered to find very small 
differences in detection of DC IS versus invasive cancer. Therefore, although the 
Oslo studies measured histopathology, neither study was able to draw significant 
conclusions about which screening modality detected more invasive and/or 
curable cancers. 
DMJST:15· 16. The DMIST design improved upon the external validity of previous 
studies because it included an enormous sample size, a large number of study 
sites and participating radiologists, a more diverse study population, and five 
different types of digital machines. The DMIST enrolled 42,760 women who 
underwent both film and digital mammography, which powered the study for 
hypothesis generation and subgroup analyses. Because of the potential to 
assign false statistical significance with multiple subgroup comparisons, the 
authors applied the Bonferroni correction equation and considered P-values less 
than .002 to be statistically significant. 
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Overall, the DMIST found no significant difference between digital and screen 
film mammography. The authors did, however, find significantly higher Area 
Under the Curve (AUC), sensitivity, and PPV of digital mammography among 
women younger than 50 years old who are pre- or peri-menopausal with dense 
breastsu This subgroup included 7,315 women, or 17.1% of the DMIST study 
population. The AUC among this subgroup of women was 0. 791 for digital 
mammography and 0.544 for screen film mammography [p=.0015]. The 
sensitivities were 0.591 for digital mammography and 0.273 for film 
mammography [p=.0013]. Finally, the PPV of digital mammography was 0.033 
and the PPV of film mammography was 0.015 [p=.0005] among these younger, 
dense-breasted women. It should be noted that the specificities of the screening 
modalities were not significantly different within this subgroup of women. 
One major concern about the DMIST, raised in editorials in The New England 
Journal of Medicine, was that digital mammography may not perform as well as 
film mammography for women older than 50 years. This concern was addressed 
in the DMIST follow-up analyses of subgroups. Among women older than 65 
years with less dense breasts, screen film mammography was more accurate 
than digital mammography in terms of AUC, sensitivity, and PPV. The AUC for 
film mammography 0.877 and for digital mammography was 0.705 in this 
subgroup of women [p=.0025]. The sensitivity of film mammography was 0.694, 
versus sensitivity of 0.532 for digital mammography [p=.031]. Because of the 
Bonferroni correction, these results just barely missed statistical significance. 17 
Nevertheless, the near-significantly better diagnostic accuracy of screen film 
mammography than digital mammography among older women without dense 
breasts raises the possibility that digital mammography could actually be more 
harmful than film mammography mammography in this large subgroup of women. 
Another weakness of the DMIST was, as in Lewin's study, interpreting 
radiologists were permitted to use previous screen film mammograms for 
comparisons. Also, if an attending radiologist found a suspicious breast lesion 
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on either a digital or a film image, (s)he was permitted to evaluate images from 
both modalities during the patient's work-up. Thus, Lewin's study and the DMIST 
introduced similar image interpretation biases. 
Like the Oslo I and II authors, the DMIST authors also recorded histopathology of 
cancers detected by each screening modality. The DMIST, however, did not 
detect enough cancers to make statistically sound conclusions about which 
screening modality was more accurate for detecting specific types of breast 
lesions. The authors conclude the "histologic findings and stage of the breast 
cancers detected by the two methods were similar. 16" 
The DMIST was designed to have superb external validity and generalizability, 
as the trial was the largest and most widespread comparison of digital and 
screen film mammography to date. The trial results do suggest better diagnostic 
performance of digital mammography among one subgroup of women. These 
results must be interpreted with caution, given the trial's threats to internal validity 
and inability to measure mortality endpoints. 
Cost-Effectiveness of Full-Field Digital Mammography 
Although reimbursement rates for mammography are different throughout the 
United States, Medicare pays about $86 for screen film and $135 for digital 
mammography. Since this price differential has important health policy 
implications, it is appropriate to consider cost-effectiveness analyses for 
population-wide use of digital mammography. Tosteson and colleagues 
performed one such analysis, from the perspective of third-party payers, in the 
Annals of Internal Medicine in January 2008. 18 The authors used a validated, 
computer-based model which incorporates the DMIST data and accounts for 
breast cancer natural history, screening and detection patterns, treatment, and 
competing-cause mortalities. Tosteson and associates considered multiple 
population-wide screening scenarios, and concluded that digital screening does 
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not offer sufficient health gains to warrant its increased cost unless its use is 
limited to younger women. Specifically, age-targeted digital screening for women 
in their forties cost $26,500 per quality-adjusted life year (QAL Y) gained, and 
age- and density-targeted digital screening for women in their forties cost 
$84,500 per QAL Y gained. Among women over 65 years, density-targeted 
digital screening cost $97,000 per OAL Y gained. Overall, the cost for all-digital 
mammography relative to all-film mammography was $331,000 per QAL Y gained. 
The primary limitation of this cost-effectiveness study was its reliance on models. 
Although the models were externally validated, they were based on predictions of 
breast cancer risk and treatment patterns, which change significantly over time 
with new medical developments. In addition, Tosteson and colleagues do not 
include costs of anxiety and fear that women experience when receiving 
mammograms or being called back for work-up of suspicious breast lesions. 
These transient hardships are difficult to capture in a cost-effectiveness analysis, 
but the authors do consider a "personal visit time" cost for breast cancer 
screening. These allowances, which range from $3 for a woman who has a true-
negative exam to $106 for a woman with a true-positive exam, may be gross 
underestimations of what women truly pay during breast cancer screening. 19 
Conclusions: Digital Mammography for Population Screening 
In the best of worlds, three questions would be answered with a "yes" before we 
implemented any wide-scale prevention strategy: "Can it work? Does it work? Is 
it worth it?" In theory, digital mammography can work as a population screening 
tool for breast cancer. The clinical trials indicate all-digital screening is certainly 
plausible, and is diagnostically comparable to screen film mammography. 
Several limitations restrict the trials' ability to answer the second question: "Does 
it work?" From a public health perspective, we are most interested in knowing if 
digital mammography "works" to decrease breast cancer mortality or provides 
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earlier detection of aggressive, treatable disease. The literature does not provide 
evidence that digital mammography "works" in this sense. The DMIST does 
show higher sensitivity of digital mammography in women less than 50 years old, 
who are pre- or peri-menopausal with dense breasts. Therefore, it can be 
approximated that more breast cancers could be detected, and burden of 
suffering could decrease, by using digital screening in just this subpopulation. 
The recent trend toward all-digital mammography makes it appropriate to 
examine the population-wide burden of breast cancer suffering that could be 
relieved with digital technology. This will shed light onto the final question: "Is it 
worth it?" Burden of suffering is estimated by considering (1) how many people 
in a given population are affected by a disease, and (2) how severe a disease is 
among those who have it. 
The majority of women diagnosed with breast cancer are over 50 years old. For 
an average woman, the risk of breast cancer doubles between ages 40 and 50, 
or increases from 0.4% to 0.8% 5-yr risk2 ° Figure 1 shows that younger women, 
who could theoretically benefit from all-digital mammography, represent only a 
small percentage of breast cancer cases. 
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Figure 2: SEER Incidence of Invasive Breast Cancer by Age21 
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Five-year survival rates provide an indicator of disease lethality, which is the 
second burden of suffering component. These survival rates, by age at breast 
cancer diagnosis, are presented in Figure 2. The graph shows that women in 
their forties may have slightly lower, but not significantly lower, 5-year breast 
cancer survival rates than do older women. 
Figure 3: SEER 5-Year Survival Rates of Invasive Breast Cancer by Age21 
Source: SEER database, National Cancer Institute, Cancer Statistics Branch 
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Figures 1 and 2 make clear that women in their forties are not the majority of 
breast cancer patients, and they do not appear to have significantly more lethal 
forms of breast cancer. Screening only this population with digital 
mammography could be cost-effective, at a theoretical $26,500 per QAL Y gained. 
However, it is inappropriate and not cost-effective to use digital screening 
mammography for the entire population. 
The research community cites expense and resources as major obstacles to 
comparing the long-term outcomes of digital versus screen film mammography. 
The Principal Investigator of the DMIST said in her interview: 
... the reason why we did what we did exactly was because we only had so 
much money. If we had more money, then we could have followed 
women. We could have gotten more years of data collection and had 
more information about annual screening mammography, and that would 
have been a stronger study. With infinite resources, which you don't have, 
we might have studied mortality as an endpoint. But, those things are 
impractical. I mean, it's just too expensive. We had one year of data 
collection, we had one year of imaging results ... and then a year to 
follow-up. So, we had a total study length of three years and it still cost us 
twenty-six and a half million dollars. 
Despite the reluctance to fund a stronger study because of cost concerns, our 
health care system has been eager to invest $331,000 per QAL Y for all-digital 
mammography. In population-wide terms, the US Census Bureau estimates the 
number of women appropriately aged for breast cancer screening, or women 
between ages forty and seventy-nine, at about 62,186,55522 If half these 
women received a digital mammogram in one year, at $135 per study, the total 
cost would be $4,197,592,463. This is estimate is $1,523,570,598 more 
expensive than would be film mammography for the same population over one 
year. Thus, using all-digital mammography for breast cancer screening could 
cost the health care system an additional 1.5 billion dollars per year. This added 
expense is more than fifty-seven times the cost of DMIST. We have therefore 
created a paradox between our refusal to fund large-scale trials to prove 
effectiveness and our willingness to pay for implementation of all-digital 
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mammography. This paradox is one of many inconsistencies that have framed 
the introduction of digital mammography to our health system. 
21 
"An Idea Whose Time Has Come" 
.. . I say openly, to the world, that we're not doing well. Still 40,000 women are 
dying a year. It's not criminal, but it's not low enough. There are still too many 
people dying. We have to acknowledge that we're finding breast cancer in some 
women when it's too late. We're doing the best we can. People get all defensive 
about it ... Some of the radiologists, they get all defensive about it: "How dare you 
attack us? We're doing the best we can; we're working our asses off; we're 
really working hard on this." Yes we are, but our tools aren't good enough. 
-- Etta Pisano, MD, Principal Investigator of DMIST 
Digital mammography was born into a time of great potential for any new breast 
cancer screening technology. In the late 1990's, our "war on cancer" was fully 
waged, with advocacy groups acting as commanders of the siege. The 
effectiveness of breast cancer screening is, however, limited because of the 
imperfect sensitivity and specificity of mammography. While the breast cancer 
lobby has been very successful in summoning enthusiasm and infrastructure for 
their cause, we have remained frustrated with breast cancer screening because, 
as Dr. Pisano stated, "our tools aren't good enough." Therefore, we may 
consider digital mammography an "idea whose time has come." John Kingdon 
states, in American politics, "an idea whose time has come is so powerful that it 
pushes aside everything that might stand in its path."6 
The War On Cancer 
Deborah Stone argues that "war" is ingrained into policy language because it 
invokes our desire to survive.23 Despite decreasing incidence and mortality rates, 
breast cancer remains the most commonly diagnosed cancer among women. 
General apprehension among healthy women about developing breast cancer 
contributes significantly to its burden of suffering. The anxiety-provoking nature 
of breast cancer screening was described by the Chairman of Duke's Radiology 
Department: 
... women coming in for screening mammography are our most difficult 
patient population, because they come in and they're anxious, and sort of 
nothing great could happen. The two things on the decision tree are: one, 
you've got an abnormality that's got to be followed up ... which makes 
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everybody unhappy ... or two, you're OK this year, we'll see you. It's not 
like "you're cured, you're healthy, go away." And all the women are 
familiar with it, and everybody's got at least friends who have had biopsies 
done. So they're very anxious, and because they're anxious and healthy, 
they turn out to be a more difficult population. 
In addition to the ambiguous nature of screening, breast cancer is also 
worrisome because it is not strongly associated with individual choices and 
habits. Popular knowledge teaches women to feel safe from lung cancer if they 
are non-smokers and from cirrhosis if they are non-drinkers. The tendency for 
breast cancer to invade a woman's life without warning or clemency perhaps 
contributed to the development of the "war on cancer." 
Advocacy groups, however, have been instrumental in popularizing this "war." 
Breast cancer advocacy is a relatively new political movement, as Betty Ford was 
one of the first women to speak openly about her disease in 197 4. This 
encouraged other women with breast cancer to discuss what had previously 
been an utterly private and even shameful diagnosis24 Betty Ford and others 
opened the floodgates of popular awareness and advocacy, and it was not 
difficult to tie breast cancer awareness and research to other goals espoused by 
the Women's Movement at the time. The Susan G. Kamen Foundation was 
founded in 1982, and other advocacy groups, including the National Breast 
Cancer Coalition and Breast Cancer Action, were founded in the mid 1990's. 
These groups have been influential agenda-setters for Congress, which 
increased funding for breast cancer research from $40 million per year to over 
$200 million per year through the 1990's.25 In the year 2007, funding for breast 
cancer included $572.4 million from the National Cancer Institute and $127.5 
million from the Department of Defense, for a total of about $700 million for 
breast cancer research through federal organizations.26• 27 Breast cancer 
advocacy groups also championed the passage of the Mammography Quality 
Standards Act in 1992, which requires all mammography centers to be licensed 
by the FDA.28 In 1993, President Bill Clinton designated October 21 as "National 
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Mammography Day" to encourage women to make yearly mammography 
appointments.29 A senior policy analyst at the Susan G. Komen Foundation 
summarized the role of advocacy groups in placing breast cancer screening on 
the national agenda when he stated: 
I think the greatest success in screening is the ... availability of 
mammograms and the education effort that's taking place ... and the 
partnerships between federal and state governments and private 
organizations like ours, the Susan G. Komen Foundation for the Cure, and 
others ... the American Cancer Society and others to get the word out that 
mammography is the gold standard in screening for breast cancer, and 
that you really have your chances of survival increase by having breast 
cancer detected early ... 
Advocacy groups have been so successful in their efforts to "get the word out" 
about the "war on cancer" that women have historically felt overly vulnerable to 
the disease. In her book Gender and American Politics, Sue Tolleson-Rinehart 
found women in the mid 1990's overestimated their risk of breast cancer by up to 
twenty-fold 24 
The public's tendency to be excessively nervous about breast cancer was 
epitomized at the beginning of this century, with a wave of concern about closing 
mammography centers and scarcity of mammograms. The actual number of 
screen film mammography centers has been well-documented by the FDA since 
2002. This declining number of film mammography centers is not particularly 
impressive, especially considering many all-digital mammography centers were 
opening during these same years: 
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Figure 4: National Screen Film Mammography Facility Count 
9400,-----------------------------------------, 
9200 
9000 
8800 
8600 
8400 
Oct, 
2002 
Oct, 
2003 
Oct, 
2004 
Oct, 
2005 
Oct, 
2006 
Oct, 
2007 
Feb, 
2008 
Source: MQSA National Statistic Archive, FDA Center for Devices and Radiological Health 
The media were responsible for amplifying the perceived mammography 
shortage, as reports of women crowded into mammography centers appeared 
especially in the northeastern newspapers. The Boston Globe published an 
article in October 2000 headlined "Radiologists are quitting, making women wait 
longer to find out if they have breast cancer."30 The article cautioned readers 
about an upcoming mammography shortage, since the number of women 
seeking mammograms doubled between the years 1985 and 2000. In 2002, a 
Newsday article headlined "A Long Wait for Mammograms" warned New York 
women they would wait between one and three months to receive mammograms. 
At the same time the media were popularizing a mammography shortage, they 
were also maintaining the "war on cancer" through digital mammography 
coverage. Of 215 digital mammography articles analyzed, 44 used the following 
war-related terms in either their headlines or opening paragraphs: weapon, war, 
struggle, fight. Among interview respondents, six out of twelve used the terms 
"fighter," "war," and/or "save lives," with four respondents repeating these words 
multiple times over the course of the interview. 
The earliest media accounts of digital screening incorporated "war" language in a 
very concrete way, because the technology was developed through cooperation 
between intelligence and medical communities. Articles with catchy titles like 
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"Medicine from Space," "CIA lets loose of technology for health use," and "From 
bombs to breast cancer aid" appeared in papers across the country. 31 -33 In 
October 1993, the Sacramento Bee described digital mammography as "a real-
life example of turning swords into plowshares."34 Several articles referenced the 
Regan Administration's "Star Wars" Defensive Initiative, stating technologies 
from this campaign would be used to enhance digital mammography. 35-37 In 
1994, the government created the "Missiles to Mammograms" program to foster 
cooperation between digital mammography innovators and the intelligence 
community. 38 The expectation for "Missiles to Mammograms" was that "space, 
defense and intelligence technology allow the unprecedented mapping of the 
landscape of the breast." 
These initial descriptions of digital mammography could appeal to the public on 
several different levels. First, the media accounts attract our sense of fantasy 
and "the unknown" in a very real way, as digital mammography was connected 
with outer space and even the Search for Extra-Terrestrial Intelligence (SETI)a2 
In addition, the notion of combining wartime technologies with a potentially life-
saving technology could be pleasing for both peace-lovers and ironic satire-
lovers. Professor JoAnne Earp believes these original accounts could have 
been purposefully marketed to adorn screening mammography, a uniquely 
female experience, with more masculine qualities: 
When you invest innovation with verbiage that surrounds it with tougher, 
more manly kind of sales aura ... such as war, or technology, or space ... 
then I think as an ad person, you think that's going to sell your sort of 
softer, "breast, women, and lower status" ... kind of take it away from that 
kind of softer, more feminized, gendered image to a more masculine, 
more "war toys," technology, masculinized image ... where the money has 
been and the technology has been and the resources have been and the 
control has been. So I think it probably was no coincidence that it was 
sold that way. 
Regardless of which sentiments these articles invoked among their readers, the 
original representations of digital mammography essentially secured its status as 
not just a new medical technology, but a new weapon in the "war on cancer." 
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The State of Breast Cancer Screening 
The FDA's approval of digital mammography in January 2000 represented the 
first upgrade in breast cancer screening for over forty years. Dr. Robert Egan 
adapted high-resolution industrial film for mammography in 1960, and that 
apparatus had remained essentially unchanged until the introduction of digital 
technology. Figure 5, on the next page, provides a timeline of significant dates in 
the history of breast cancer screening. 
27 
Figure 5: Important Dates in the History of Breast Cancer Screening & Digital Mammography 
1895 -Wilhelm Roentgen develops the X-ray process39 
1960- Dr. Robert Egan adapts high-resolution industrial film for mammography, allowing simple and 
reproducible mammograms with improved image detail40 
1963 -Initiation of the first randomized controlled trial of breast cancer screening by the Health Insurance 
Plan of New York. Data from 18 years of follow-up indicates 25 percent reduction in breast cancer mortality 
among women over 50 years who received screening mammography40· 41 
1974- Betty Ford speaks openly about her breast cancer diagnosis" 
1982- Susan G. Kamen Foundation for the Cure founded25 
1986- American Cancer Society and American College of Radiology develop breast cancer screening 
accreditation program40 
1992- Mammography Quality Standards Act requires all mammography facilities to be licensed by the 
FDA28 
*NCI designates digital mammography "the imaging technology with the highest potential" for detecting and 
diagnosing breast cancer42 
1993- Suzanne Fletcher and colleagues publish evidence review, "Report of the International Workshop on 
Screening for Breast Cancer," which acknowledges unknown benefit of screening for women aged 40-4943 
*President Bill Clinton designates October 21" as National Mammography Day29 
1994- "Missiles to Mammograms" program launched by Public Health Service's Office on Women's Health, 
with the pur;pose of digital technology sharing between the intelligence community and mammography 
innovators3 · 44' 45 
1997- NIH Consensus Development Conference on Breast Cancer Screening for Women Ages 40 to 49 
does not recommend universal mammography for women in their forties; decision met with great resistance 
from breast cancer screening enthusiasts and politicians46 
1998- NEJM article reports cumulative risk of false positive mammogram at 49.1% after 10 
mammograms47' 48 
*FDA approves lmageChecker for mammography double-check49· 50 
2000- FDA approves G. E.'s digital mammography machine, the Senographe 2000D®51 
2001 - National Cancer Institute awards team of investigators, headed by Dr. Etta Pisano, $26 million grant 
to study digital mammography52 
*Medicare coverage for digital mammography increases to 150 percent of traditional mammography 
reimbursement rates53 
2002- Tommy Thompson announces federal guidelines, which strongly recommend mammography for 
women aged 40-50 years28 
*BiueCross, BlueShield North Carolina begins reimbursing for digital mammography at the same rate as 
screen film mammographl4 
2003- FDA starts providing accreditation to mammography facilities which only use digital technolog/5 
2005- DMIST results show digital mammography more effective for younger, dense-breasted women 
2007- UNC converts to all-digital mammography56 
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Other radiology tools, such as CT, MRI, and PET scans, have been digital since 
their inception. These sophisticated technologies have paved the way for 
popular concepts like "the digital revolution" and "wireless medicine." For 
example, a January 1998 article in the Dallas Morning News reported, "More 
radiologists and hospital administrators seem to be dreaming in digital these 
days because a new generation of digital technology promises to enhance clarity, 
reduce costs and improve convenience."57 Film mammography, which requires a 
dark room for image development and a view box for analysis, seems archaic 
compared to other radiology technologies. Duke's Director of Breast Imaging 
described the state of breast cancer screening in somewhat hyperbolic terms: 
The entire rest of the radiology department has been on soft copy display 
-that means CAT scans, MRI, even X-rays of big toes ... for many, many 
years. So, as radiologists we've had experience using soft copy displays 
when we get our call. 
The importance of digital mammography as "technology" was demonstrated in 
other interviews, as the following respondents mentioned either "computers" or 
"technology" several times throughout our encounter: 
Figure 6: Keyword Frequency: Computerrrechnology 
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The most remarkable feature of this keyword count is respondents affiliated with 
UNC Hospitals generally mentioned "computers" and/or "technology" more 
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frequently than did respondents affiliated with Duke University. The trend is 
telling: UNC converted to all-digital technology early, and has a stake in 
embracing the technology in which it has made a substantial early investment. 
Duke, on the other hand, is only now overhauling its screen film systems and 
does not evince the language of early adopters. 
The media have also been attuned to the innovative aspect of digital 
mammography, and have used concrete, simple metaphors to help explain the 
technology to the public. These include comparing digital mammography to word 
processors rather than type-writers, fax machines rather than snail mail, and 
digital cameras rather than traditional cameras. In fact, 10% of reviewed articles 
likened digital mammography to digital cameras, and about two-thirds of articles 
that explained the mechanics of digital mammography used the analogy of either 
a digital camera or a word processor. A Newsday article published in September 
2005 provided one such typical description of digital mammography: "Both digital 
and film mammograms require the use of X-rays to produce an image. But 
digital mammography, which is similar to taking pictures with a digital camera, 
allows doctors to view the mammogram on a computer and to change the 
contrast on their screens to view suspicious areas."58 The digital camera 
metaphor, which is even being used by clinicians, makes digital mammography 
very palatable for the average woman and also draws on our fondness for the 
newest and most convenient technologies. 
Breast imaging specialists also like new technology, especially when it may lead 
to higher status and more reimbursement. Breast specialists have perceived 
themselves to be underpaid and subject to higher rates of lawsuits, compared to 
other radiologists. The Director of Breast Imaging at UNC described the inherent 
humility associated with reading mammograms as follows: 
I'll just tell you that the history for breast imaging and mammography ... 
that Medicare and all insurance systems are typically low for reimbursing 
for mammograms ... That's another reason why a lot of people don't even 
want to go into it. It's not just the liability, but it's not a very thankful, high-
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paying reimbursement. .. by them (digital mammograms) having a little bit 
higher reimbursement, it's just starting to make the tables ... in my opinion, 
from my side of the fence ... a little bit better. The reimbursement for 
mammography ... for what people pay ... it's just so low. 
Media have also reported on the relatively lower compensation and higher 
liability for breast imaging. 59 Numerous articles have described mammography 
as a money-loser, and the New York Times even quoted a renowned breast 
imaging specialist who described fellowships in mammography as a "lousy 
career move."60 Other articles have described breast imaging specialists as the 
"most highly sued radiologists." 
Between August 1985 and 1995, the Physician Insurers Association of America 
(PIAA) tracked over 125,000 medical malpractice claims for missed breast 
cancer diagnoses, and found breast cancer-related claims yielded higher 
settlements than did any other malpractice suits except for those arising from 
cases of brain-damaged infants. These findings led the American College of 
Radiology (ACR) to support regular screening mammography for women in their 
forties, supposedly to decrease the number of missed breast cancers. 61 
The perception of higher numbers of lawsuits against radiologists who read 
mammograms was reaffirmed by several interview respondents, including Dr. 
Earp, who commented: 
Breast cancer is the first. .. among those diseases that cause lawsuits. 
mean, there are papers out there that show, of the suits that happen ... 
breast cancer was the first cause of lawsuits. 
Partially in response to these widespread malpractice concerns, the St. 
Petersburg Times conducted research into malpractice history for breast imaging 
specialists in Florida, and found no significant difference in number of lawsuits or 
malpractice insurance rates for radiologists between 1991 and 2002.62 
Nevertheless, government officials in Florida and other states proposed 
legislation specifically to protect radiologists from lawsuits for missed breast 
cancers. This example of policy change based on perception of lawsuits, rather 
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than evidence about the actual amount of litigation, may be considered a litmus 
test for the political strength of breast imagers and screening advocates. It is not 
surprising that these groups were very influential in launching the adoption and 
widespread distribution of digital mammography. 
In addition to digital mammography's potential to advance what might be thought 
of as the "social status" of breast imaging, the technology also brought great 
hope for more accurate diagnoses. Digital mammography came to market during 
a time of intense debate, among professional organizations and cancer 
specialists, about the true value of breast cancer screening. In October 1993, 
the Journal of the National Cancer Institute published the "Report of the 
International Workshop on Screening for Breast Cancer." Investigators reviewed 
eight major randomized controlled trials of breast cancer screening, and found a 
one-third reduction in mortality for screening women ages 50-69, but no benefit 
for screening women in their forties 43 In 1994, the American Cancer Society 
(ACS) and the National Cancer Institute (NCI) engaged in a fierce discussion 
about mammograms for women in their forties, with the ACS supporting 
screening and the NCI concerned about potential harms offalse results. 63 In 
April 1998, even more public attention was drawn to the potential for false 
positives when the New England Journal of Medicine published an analysis 
estimating the cumulative risk of a false positive result at 49.1% over the course 
of 10 years, or 10 mammograms47 False negative screenings have also drawn 
media attention, as an article published in the Houston Chronicle explained: "It 
(mammography) misses 20 percent to 25 percent of cancers in women under 50 
and 8 percent to 10 percent in women over 50 ... 64" 
Many interview respondents reiterated these longstanding concerns about the 
diagnostic accuracy of screening mammography. The senior policy analyst at 
the Susan G. Kamen foundation named "false positives" as the greatest threat to 
breast cancer screening. The Chairman of Radiology at Duke also lamented the 
inaccuracy of screening mammography, and its effect on patients: 
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So the number of false positives ... if you look at the data on how many 
biopsies and things we do, that turn out to be normal. .. The patients don't 
usually get horrendously upset, in the sense that, in the world of women, 
having a breast biopsy is fairly commonplace. In a way, doctors always 
say ... "three quarters of these are going to be normal, so don't get 
yourself too excited." The other side of that though, is if only three-
quarters of those are normal, couldn't we do a better job about figuring 
that out before you have to worry for days? ... and needles ... and all that 
kind of stuff. We should be doing a better job. 
The uncertain analyses of screening mammography have been accented by 
several definitive, though not necessarily evidence-based, statements by public 
health officials. For example, in March 2000, the United States Preventive 
Services Task Force (USPSTF) developed a guideline for screening 
mammography in women over 40 years old. The USPSTF gave their guideline a 
"B" recommendation, indicating fair evidence in favor of screening 
mammography. Despite the "B" recommendation, Tommy Thompson 
emphatically announced to American women that benefits of screening 
mammography outweigh potential harms. Thompson said the federal 
government was sending a "powerful and clear" message to women: "If you are 
40 or older, get screened for breast cancer with mammography every one to two 
years."65 
Despite Tommy Thompson's declaration, confusion and debate have continued 
to surround breast cancer screening. One reporter for the Chicago Tribune 
perhaps phrased it best in October 2004 when she wrote: "Many women are 
confused about mammography, and it's no wonder. For years, doctors have been 
debating and changing breast cancer screening guidelines. It seems like our bras 
last longer than mammography recommendations do."66 
Conclusion 
Digital mammography, "an idea whose time has come," entered health care as a 
technology that could potentially relieve the uncertainties and frustrations 
inherent with screen film mammograms. It could provide a new "weapon" for the 
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advocacy groups' "war on cancer," update the mammography process, boost the 
prestige and profitability of breast imaging, and provide greater diagnostic 
accuracy in screening mammography. The New York Times described these 
popular hopes for digital technology in a January 2001 article entitled 
"Mammography's Next Step is Assessed:" 
... its (film mammography) imperfect record is one of the great frustrations 
of cancer professionals and women alike. So it is no surprise that the 
Food and Drug Administration's approval of the first digital mammography 
unit early this year was met with much hope and enthusiasm.67 
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The FDA as a Gatekeeper 
We are a "gatekeeper" ... and we need to assure that things on the market are 
not going to hurt people. Once we can assure ourselves of that, then I think we 
need to allow technologies on the market with the understanding that we will get 
more information as time goes on. 
-- Daniel Schultz, MD, FDA Director, Center for Devices and Radiological Health 
General Electric's Senographe 2000D® full-field digital mammography unit was 
approved by the United States FDA in January 2000. As with other medical 
technologies, FDA approval was crucial for distribution of digital mammography 
because it allowed General Electric, and other private vendors like Hologic, 
Fischer, and Fuji, to begin widespread marketing to patients and clinicians. In 
addition, FDA approval was a necessary step before the federal government 
could increase its Medicare reimbursement of digital mammography to 150 
percent of screen film mammography reimbursement. 53 
The FDA's approval happened at an ambiguous time in the accrual of 
effectiveness data for digital mammography. In January 2000, none of the major 
trials comparing digital with screen film mammography had been published. The 
study by Lewin and associates was not published until March 2001 and the Oslo 
I and II studies were published in 2003 and 2004, respectively. The DMIST did 
not even have funding until one year after the FDA approved digital 
mammography. Dr. Schultz summarized the approval process as follows: 
... as with many technologies, we were able to provide reasonable 
assurance of safety and effectiveness, which is the standard that we use 
and that Congress has given us to approve new medical devices. So, 
what that means is that in many cases we don't know everything that there 
is to know and we fully expect that additional information will be gathered 
over time. 
Only a patchwork picture of the approval process may be discerned from media 
accounts and interview respondents affiliated with the FDA and/or digital 
mammography. Several respondents acknowledged the necessary connection 
between public and private sectors during the FDA approval process. The 
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Administrative Director of UNC's Radiology Department described Dr. Pisano's 
cooperation with both private companies and the FDA: 
Etta helped some companies achieve their FDA clearance. She's also 
had a role in advising the FDA on what was reasonable, to assess the 
turnover ... what was acceptable for the FDA to approve digital imaging. 
Given the critical roles of innovators and private companies in technology 
development, it is not accurate to consider them "external entities" trying to 
impose their agendas on the FDA. Nor is it appropriate to expect FDA staff of 
Advisory Committee members to evaluate new medical devices without input 
from these innovators and private companies. 
In the case of digital mammography, both breast imaging specialists and 
technology development companies were eager for rapid approval. UNC's 
Administrative Director of Radiology described the environment prior to buying 
digital equipment: 
Now, when it gets closer to, you know, hitting the market and the vendors 
were so excited about the eminent FDA approval. .. and then postponed, 
postponed, postponed. The vendors were trying to stage the equipment. 
In some ways, we were willing to purchase, but if it's not FDA approved ... 
we don't go for it. .. but we will continue clinical research work on the fringe, 
until it is approved. And then the vendors got to the point where they were 
so anxious to sell. .. that they got a little bit reluctant, because they thought 
FDA was right around the corner. As soon as they got FDA, they'd be 
able to sell. 
The administrator's language in this passage, particularly his use of the words 
"excitement," "anxious," and his repetition of "postponed," captures the great 
anticipation with which private companies must have awaited FDA approval. 
Private companies, however, may not have been as eager for approval as were 
breast imaging specialists. Dr. Pisano expressed frustration with the process 
from her perspective as an innovator: 
So, I just feel. .. one of the things that frustrates me about the pace of the 
change is I've been in this field for 19 years now, and look at how many 
new tools we've gotten, and digital is the most promising one ... and it took 
a long time to get it. And there are new ones on the horizon and it's going 
to take a long time to get them, and we have a generation of women 
36 
dealing with breast cancer. My generation, your generation ... So I feel 
really a huge pressure to try and move things forward and get things done 
more quickly. It really bothers me that it takes so long ... and that we're 
making such slow progress. I wish the breast cancer community would 
focus on that, because the FDA. .. it's not just the FDA, it's the companies, 
it's radiologists, it's everybody. 
Dr. Pisano's dissatisfaction with the approval process, which almost took on the 
tone of a personal mission in this excerpt, has been echoed by other groups of 
breast imaging specialists. One group of radiologists wrote a statement of 
concern about the digital mammography approval process for Diagnostic Imaging 
in December 1999. Their statement was also published in a USA Today article 
entitled "Going digital Proponents say it's time the FDA updates mammography 
system."68 The group sent the following joint message to the federal 
government: "We believe that the review process, which has extended for more 
than three years, is unduly prolonged and complicated." 
Dr. Schultz acknowledged pressures from private vendors and breast specialists 
during his interview: "Um, there's always pressure from companies to approve 
their products as quickly as possible. I mean, that is a given in what we do." Dr. 
Schultz also noted that in the case of digital mammography, pressure from 
technology developers was so great that the agency needed to "take a stand:" 
There was a lot of pressure, and a lot of it actually was coming from very 
prominent clinicians, and even academic clinicians, who felt that the mere 
fact that the image was ... appeared to be ... a higher-quality image ... 
should in fact be enough for us to approve the technology, as we had for 
other types of digital technologies. And I think this was a case where we 
really needed to sort of take a stand and say that, you know ... the fact that 
it's a better picture, or what appears to be a better picture, is not enough. 
The digital mammography approval process was thus caught between the 
agendas of renowned innovators and the FDA's mandate to ensure public safety. 
The process was not driven by ensuring digital mammography could maximize 
positive health outcomes for American women. Rather, it became more about 
finding mechanisms to satisfy the different stakeholder groups affiliated with the 
technology. 
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Conflicting interests even spilled into the FDA's internal discussions about the 
technology. While certain FDA members pushed for rapid approval, others 
called for more extensive, head-to-head comparisons of digital and film 
mammography. A USA Today article reported specific information about dueling 
perspectives of the agency members, certain top FDA officials, and the advisory 
committee.68 The article reads: 
The agency wants manufacturers to conduct screening trials that 
would compare digital and film mammography head-to-head. Such a trial 
would need thousands of patients and cost millions of dollars. 
"This is not an industry that's used to those kinds of costs," says 
David Feigal, top medical devices official at the FDA. 
But the advisory committee, fearing that patients bear the cost of a 
screening trial, urged the FDA not to require one of G.E. 
The end result of these conflicts, both between the FDA and "outside" groups, 
and among FDA members themselves, was a compromise. After a three-year 
review process, the FDA had sufficient evidence to convince itself of digital 
mammography's safety and effectiveness. Dr. Schultz described the 
compromise: 
It was one of those situations, I think, where nobody was totally happy with 
us. So I think we were probably in close to the right place. 
In retrospect, the FDA was actually "close to the right place," because clinical 
trials have now demonstrated similar diagnostic accuracies of digital and film 
mammography. Data collection for the actual approval process, however, 
appears to have been far messier. Specifics are unclear about which data were 
collected, and what evidence was gathered, before the Senographe 2000D® was 
approved in 2000. In our April 2008 interview, Dr. Schultz gave one account of 
the FDA's protocol: 
... I think what we were able to do over time, with a lot of input from our 
statisticians and working with companies ... we were able to design studies 
that were more in the range, I believe, of 1,000 to 1,500 or something like 
that... that were enriched with additional cancer patients that allowed us to 
approve the devices with the assurance that I told you about. .. you know, 
that we were not. .. that clinical performance would not be adversely 
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affected and still get that kind of clinical information, without the large trials 
that were originally proposed. 
The Dallas Morning News reported slightly different data collection in February 
2000, although Dr. Schultz was cited as the newspaper's key informant. The 
article stated: "In studies of 625 women, a printout of the mammogram from the 
digital machine was as effective in detecting breast cancer as standard film 
mammograms." 
These descriptions by Dr. Schultz and the Dallas Morning News are vague, 
particularly with regard to the number of investigational cases used to compare 
screen film and digital mammograms. Uncertainties were mirrored in press 
reports, as the Dallas Morning News article warned readers: "Digital 
mammograms appear as good as - but not better than - regular mammograms 
in detecting breast cancer ... " 
Ultimately, digital mammography won FDA approval on the basis of these 
uncertain data. The FDA's approval legitimized the subsequent increase in 
Medicare reimbursement for digital mammograms, which undoubtedly catalyzed 
the spread of the technology. Higher reimbursement rates made the upgrade 
from film to digital technology invisible, from a cost perspective, for many medical 
practices. In addition, the more generous Medicare reimbursement set a new 
standard for private insurance companies to increase their payments for digital 
mammography. Details about the justifications and reasoning behind higher 
Medicare payments for digital mammography are uncertain. At the time of this 
writing, no Medicare officials were available to comment on funding 
appropriations for digital mammography. The 2001 increase in Medicare funding 
for digital mammography, however, was certainly dependent on the technology's 
FDA approval. 
Since Medicare almost immediately started reimbursing more generously for 
digital than screen film mammography, free market forces were prevented from 
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entirely determining the fate of the technology. Also because of compromises, 
however, providers did not have rigorous evidence to offer a convincing 
demonstration of digital mammography's effectiveness. The FDA approval 
process resulted in an allocation of public funds for an ambiguously effective 
intervention. The FDA, which is inextricably linked with private technology 
developers and innovators, opened the floodgate and allowed the Senographe 
2000D® to flow through health care. 
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Perceptions with Real Consequences 
So, not to my surprise, but a little bit to my surprise, we get rid of all-film screen 
and we go to all-digital when there's not data to show that's effective. But I 
understand why because one of my most favorite of all aphorisms, sentences ... I 
attribute it to WI. Thomas, sociologist in the 1920's, who said: 
"Things that are perceived as real are real in their consequences." 
-- Professor JoAnne Earp, SeD 
As with many of our new technologies, the widespread distribution of digital 
mammography has been catalyzed by anecdotal success stories and even 
misinterpretation of facts by leaders in health care. This phenomenon is likely 
because, as Deborah Stone writes, " ... facts do not exist independent of 
interpretive lenses, and they come clothed in words and numbers." Facts about 
digital mammography have been disseminated in a disorganized way, with the 
media and even key stakeholders in breast cancer screening receiving their 
information second- or third-hand rather than directly from the DMIST results 
section. Certain attributes of digital mammography have been inappropriately 
magnified, leading some decision-makers to justify their actions with incomplete 
data. 
The Fate of the Evidence 
Two popular perceptions about digital mammography have led the general public 
and radiologists to accept its superiority over screen film mammography. First, 
positive findings from the DMIST and other trials have been overstated by the 
medical literature, digital mammography enthusiasts, and the media. Second, 
people have exaggerated the theoretical and logistical advantages of digital 
mammography. 
Both these perceptions can be traced to the presentation of digital 
mammography in medical literature. For example, in the DMIST abstract, 
authors report: "The overall diagnostic accuracy of digital and film 
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mammography as a means of screening for breast cancer is similar, but digital 
mammography is more accurate in women under the age of 50 years, women 
with radiographically dense breasts, and pre-menopausal or peri-menopausal 
women."15 This favorable presentation of digital technology could have been 
motivated by publication bias, or more publication opportunities for trials with 
positive, significant results. Dr. Pisano explained her rationale for UNC's 
adoption of all-digital mammography as follows: 
In fact, I was pushing for it before DMIST was even out, because I felt like, 
"we know what the results are, it would be irresponsible not to do it." I felt 
that... we knew it would be better for these dense-breasted women, and 
therefore we were going to have a hard time serving 60% of the 
population until we ... you know, we had no digital equipment except for in 
the diagnostic center before we converted. 
Although Dr. Pisano knows the DMIST well, her statement was not entirely 
congruent with the trial's results. Subgroup analyses of the DMIST results were 
published in Diagnostic Radiology in February 2008. The analyses show digital 
imaging is only statistically significantly better than screen film imaging for one 
subgroup of women with all the following characteristics: 40-50 years old, pre- or 
peri-menopausal, and with dense breasts. No other subgroup, including older 
women with dense breasts or younger women with non-dense breasts, showed a 
significant diagnostic advantage of digital over film mammography. The 
subgroup of women who actually had a statistically significantly better cancer 
detection rate with digital mammography only comprised 17% of the DMIST 
study population. 17 This percentage does not match Dr. Pisano's suggestion that 
60% of women screened would actually benefit from digital mammography. 
Dr. Earp addressed this apparent disjunction between actual trial results and the 
representation of results when she stated: 
Etta used to say to me, "we don't need all digital. It didn't work." She's not 
saying that now, she's Dean now, and she's saying we have to have it for 
everybody. She's very conscious, you have to be, of what the legislatures 
think, what the people think, what the payers think, what the insurance 
companies think ... versus what the science says. I mean, it's a tough role. 
I don't envy her. 
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Notably, in past press releases, Dr. Pisano has also given more neutral 
evaluations of digital mammography, stating it is "not a magic bullet."69 She has 
advised women "not to rush out and get a digital mammogram."70 The overall 
message passed from the medical literature to the public, however, is that digital 
mammography confers diagnostic advantage over film mammography for a 
significant proportion of women. 
The media have been major vectors of information between the research 
community and the general public. Both the Chairman of Radiology and the 
Director of Breast Imaging at Duke recognized the importance of media in Duke's 
decision to convert from film to digital screening. The Chairman of Radiology 
explained media influence as follows: 
My understanding about what that study showed was that essentially 
digital had an advantage, really in women with denser breast tissue, but 
sort of in the 40 to 50 age group .... Now when the press put that out, it 
came out sounding a little bit different than that ... so what happened was 
women reading this stuff said, "Oh gosh, I've got to have the digital ones. 
It's better." So fortunately for us, we had some digital equipment. .. but 
unfortunately not enough at the time to take care of all women who 
wanted to be screened. 
Duke's Director of Breast Imaging echoed the Chairman's view about digital 
mammography being inaccurately presented to the general public: 
The message that has gotten out, through no fault of the ACRIN 
(American College of Radiology Imaging Network) folks, but because it's 
easy ... it's complicated stuff ... so it's easy for CNN to report digital is 
better. And that's the message that's gotten out. Even though I think the 
message is more nuanced than that. It's better for some, not better for 
others, and it's probably equivalent for many. 
Although both Duke radiologists point to the media as a potential source of the 
public's misinformation, findings from my analysis of media accounts were not 
consistent with their hypotheses. Rather, it appears the media served to amplify 
messages from both the medical literature and elites in digital mammography, 
who gave an overall neutral to positive evaluation of the technology. Of 215 
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newspaper articles reviewed for this study, 21 articles were written with the 
purpose of presenting DMIST results. The majority of these articles had either 
positive or neutral tones in their headlines and opening paragraphs, with the 
exception of one article: 
Figure 7: Newspaper Portrayal of DMIST Results 
o Positive 
o Neutral 
• Negative 
An example of a positive Wall Street Journal article's headline read: "Digital 
Mammograms Excel in Study."70 A more neutral Chicago Tribune article's 
headline read: "Digital screening for breast cancer gets mixed review- More 
accurate for young, but not overall."71 Finally, the negative digital mammography 
article in the Washington Post was headlined "Finding more Cancer is not the 
Answer."72 Although the 21 DMIST newspaper articles accurately reflected the 
neutral to positive tone with which primary investigators represented their results, 
readers of the media were probably more impressed with the positively-toned 
articles. Women's tendency to be more influenced by the positive articles is 
perhaps attributable to social factors including public desire for dichotomy, with 
news situations being either "good" or "bad." 
Each of the 21 newspaper articles presenting the DMIST results also mentioned 
additional, theoretical advantages of digital mammography. These advantages 
originated from the DMIST article, and include "easier access to images and 
computer-assisted diagnosis; improved means of transmission, retrieval, and 
storage of images; and the use of a lower average dose of radiation without a 
44 
compromise in diagnostic accuracy."16 Enthusiasm for the theoretical benefits of 
digital technology was also expressed during interviews. The chart below 
presents responses to the interview question: "What is the main advantage of 
digital mammography?" 
Figure 8: Best Characteristics of Digital Mammography as Identified by Interview 
Respondents 
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Respondents affiliated with UNC were more likely to cite evidence from DMIST 
as the main advantage of digital mammography, whereas respondents without a 
connection to UNC were likely to mention other advantages. This phenomenon 
is likely because UNC was the central organizing center for DMIST, and 
respondents were more heavily invested in the study's positive findings. The 
Director of Breast Imaging at Duke shared his understanding about the relative 
importance of evidence for digital mammography: 
... So, do I think it's medically the best thing for all patients to be all-digital? 
No! I think that Etta's data and the ACRIN data are pretty clear that that's 
not the case ... So, no, I don't think anyone can really make the argument 
that patients are medically better served by being all-digital. But there's 
more to medicine than being 100% purist about the exact right test. .. So 
practical considerations have to be taken into account. .. 
The problem with "practical considerations," as presented by the media and 
interview respondents, is that many of these considerations are only supported 
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by theory and anecdotal evidence. The following are examples of digital 
mammography characteristics that have been touted as advantageous; however, 
on closer examination, these advantages are not as real as they are perceived to 
be. 
Less pain, less radiation. Out of 215 media articles reviewed for this analysis, 
38 mentioned digital mammography's ability to reduce pain and/or radiation 
exposure. For example, a 1998 article in the Chicago Tribune was titled 
"Remodel Mammography? It couldn't hurt." The article predicted digital 
mammography might relieve women from the discomfort of the "slam-o-gram."73 
A later article in the Detroit Free Press entitled "A New Day for Women" claimed 
digital mammography could decrease breast compression time, and therefore 
radiation exposure and pain, by 15-20 minutes. This article quoted one recipient 
of a digital mammogram who said she felt "no pain at all."53 
These characteristics of digital mammography, if accurate, would indeed be very 
advantageous for women. Radiologists, however, do not validate them. All 
radiologists interviewed confirmed no difference between digital and screen film 
mammography in terms of a woman's subjective experience. The Director of 
Breast Imaging at Duke commented on this discrepancy between women's 
expectations and the procedure's actual mechanics: 
We have had patients say that, "the exam was much more comfortable 
because it was digital," and I think that's placebo effect. They're really, 
basically mechanically extremely alike. 
Radiologists also agreed that radiation dose delivered during digital 
mammography would not be appreciably lower than during screen film 
mammography. The Chairman of Radiology at Duke confirmed digital could 
potentially deliver less radiation, but at the expense of image quality: 
... because it turns out that if you turn up the dose a little then the image 
looks even better, and the film doesn't. .. if it were film it goes black. But if 
it's digital it doesn't go black. And so we saw in everywhere we had digital 
detectors, radiation dose creep. 
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Lower recall rates. Many early newspaper articles about digital mammography 
emphasized its potential for lower recall rates than screen film mammography?4· 
75 For example, an October 2000 article in the Chicago Tribune featured a breast 
imaging specialist saying: 
"Now we can manipulate the digital mammogram on the computer rather 
than manipulate the women ... We can zoom in on an area, lighten it or 
darken it. Before, the only way to zoom in was to bring the woman 
back."76 
Although the public has perceived lower recall rates with digital technology, both 
the medical literature and the radiologists interviewed have indicated no overall, 
significant difference in recall between screening modalities. In the study by 
Lewin and associates, authors found a significantly lower recall rate for digital 
mammography than for screen film mammography. Specifically, Lewin and 
colleagues found an 11.8% recall rate for digital mammography and a 14.9% 
recall rate for screen film mammography (p<.001 ). 11 In the Oslo II study, 
however, women aged 50-69 had a 3.8% recall rate for digital mammography 
and a 2.5% recall rate for screen film mammography (p<.05)n No significant 
difference in recall rates were found in either the Oslo I study or the DMIST. 
The Director of Breast Imaging at Duke believes the public's misunderstanding 
regarding lower recall rates could be attributable to a different system for reading 
digital versus screen film mammograms: 
... And we do some what we call "batch screening" where the patient gets 
their 4 views and goes home. And we review them, generally the next day, 
in "batch mode" ... you know, we read 60 mammograms at a time and 
send them a letter saying either "it's fine" or "give me a phone call to come 
back." With digital, you can't really do the "batch mode," because we only 
have one reading station ... those all get read "online." We know there's a 
difference in recall for patients right there. It's much easier to just say, "ah, 
let's just press that out, whatever it is ... " As opposed to, you have to call 
the patient back from an hour away, or a half hour away .... 
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The hypothetically lower recall rates for digital mammography could therefore be 
a function of the system radiologists use to interpret digital images, rather than 
superiority of the technology itself. A recent New York Times article reported, as 
clinics switch from film to digital technology, many more women are actually 
being recalled than the accepted volume of 10% with screen film 
mammography. 77 Since articles like this have arrived late in the diffusion of 
digital mammography, however, they may not deter the technology's continued 
growth. 
Image sharing. One of the most intriguing aspects of having mammograms on 
computer is the possibility for long-distance image sharing. The media seized 
this idea of distance medicine, or telemedicine, in their early coverage of digital 
mammography. In April 1997, the St. Petersburg Times quoted a very optimistic 
breast imaging specialist who thought: "A radiologist could sit in a nice, cool 
office over here and read mammograms from the Andes Mountains ported over 
by satellite."78 In September 2002, an Orange County Register article 
proclaimed that, since digital mammograms are recorded on "computer code," 
they could be "downloaded and sent to staff doctors down the hall or to 
specialists across the country."79 A December 2003 article in the New York Daily 
News described digital mammography as having the ability to "send high-
resolution images anywhere in the world to be read by specialists." 
Despite the public's enthusiasm for image sharing, radiologists have been more 
tentative about the logistics of using digital technology as a vehicle for 
transferring mammograms. The Chairman of Radiology at Duke cautioned that 
image sharing is not likely to result in detecting more breast cancers: 
The unfortunate problem is ... that, particularly in screening is, to share the 
images ... if you just said, "well, I'm out here and here's a puzzling case, let 
me get an expert opinion." It's usually not the puzzling cases that are the 
problem. It's where you just miss the finding. So the question is: Would 
those physicians who are doing it on the outside just begin to shift their 
images to us? I don't think so. Could they share an interesting case? 
Absolutely. Would it be easier to share? Absolutely. Urn, but that's not 
what we see happening most of the time. If they have what they think is a 
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difficult case, they do. But I'm more concerned about the ones that they 
just flat out miss. 
In addition to these concerns about the utility of image sharing, infrastructural 
challenges are also prohibiting transfer of digital mammograms. In fact, digital 
images are only easy to share because, as articulated by UNC's Director of 
Breast imaging, " ... it's much faster to ship something smaller than large 
packages of films ... um, it'll be cheaper postage too because you can put more 
information on a CD ... " Respondents indicated that infrastructural challenges will 
continue to be the greatest obstacle for image sharing. These challenges are 
unique for different institutions and health care providers. The Director of Breast 
Imaging at Duke, for example, shared his frustrations with digital communication 
set-up: 
... send an image here? I don't see that happening any time in the 
foreseeable future. I mean, you could easily foresee how it would be 
possible. But right now it would require someone else's PACS (Picture 
Archiving and Communication System) to talk to my PACS. We can 
barely get our PACS to talk ... you know, it's difficult enough to get it to talk 
to our ultrasound machine down the hall. .. getting it to accept images from 
across the country is certainly technically possible, I just don't see it being 
likely. 
In addition to infrastructural issues, UNC's Director of Breast Imaging cited 
confidentiality as another barrier to transferring an individual's mammogram 
between locations: 
Emailing you can't do with the images because of the federal. .. the HIPAA 
(Health Insurance and Portability Accountability Act) laws with patient 
privacy. You can't really just email 'em. 
After speaking with radiologists, the idea of image sharing does not seem as 
feasible or promising. The most realistic application of digital image transfer is 
telemedicine, where satellite clinics electronically transport their mammograms to 
central processing facilities. This arrangement is uncommon, however, and data 
are not available to prove the effectiveness of telemedicine. The public's naive 
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idea about digital image sharing is not likely to happen in the near future, but this 
perception has been instrumental in our adoption of digital mammography. 
Efficiency. Both radiologists and non-radiologists seem to agree that increased 
clinical efficiency is possible with digital mammography. The Director of Breast 
Imaging at UNC praised digital mammography for enabling radiologists to leave 
their roles as "one-armed paper hangers" and retrieve images with "just the click 
of a mouse." Other interview respondents mentioned keywords "easy," 
"efficient," or "fast" in their descriptions of the technology: 
Figure 9: Keyword Frequency: Easy/Fast/Efficient/Instant 
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The most striking aspect of this keyword analysis is the tendency of UNC 
affiliates to mention "efficiency words" more frequently than did other 
respondents. Again, this could be attributable to UNC's early adoption of all-
digital mammography, and the desire of leaders at UNC to reaffirm the hospital's 
role as a leader and innovator. Even the radiologists affiliated with Duke, 
however, mentioned "efficiency words" multiple times during their interviews. 
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The media have also presented anecdotal data suggesting greater efficiency of 
digital mammography. For example, in January 2001, the Houston Chronicle 
interviewed Baylor's director of breast imaging, who praised digital mammograms 
as being available "anytime and anywhere."80 In February 2004, the New York 
Post put a celebrity spin on digital mammography's effectiveness by quoting 
Mayor Bloomberg at a press conference: 
"Early detection is crucial, and digital mammography dramatically speeds 
up the screening process, cuts waiting times and saves lives."81 
The problem with these popular claims about efficiency is lack of data showing 
higher patient throughput with digital systems. Radiologists striving to implement 
all-digital systems often experience the exact opposite of efficiency before their 
systems are fully functional. Departments continue to install digital systems, 
though, because they hope digital will eventually become faster. The Director of 
Breast Imaging at Duke acknowledged his discouraging experiences with digital 
technology thus far: 
Well, I gotta tell ya ... at first we had no improvements in work flow in the 
one room that we had digital. That was a disaster for us, that room has 
been a disaster. .. So the supposed improvement in patient throughput 
that you're supposed to see ... we experienced just the opposite. We had 
a net decrease in patient throughput because the room wasn't operating. 
Um, once we got the room stabilized ... that only took about a year and a 
half ... once we got the room stabilized, now we are seeing much better 
throughput. 
It is uncertain, based on the Director's account, whether Duke's "better 
throughput" is "better" as compared to screen film mammography or "better" than 
their throughput prior to stabilizing the room. 
At the other end of the spectrum, radiologists who have already implemented all-
digital mammography are also speaking about the system's efficiency, but only in 
terms of personal experience. The Director of Breast Imaging at UNC 
recognizes the problem of anecdotal evidence, and has designed a study to 
compare speeds of digital versus film mammography interpretation times. 
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Regardless of what studies are conducted to examine efficiency, it will be difficult 
to statistically prove only slightly shorter digital mammography interpretation 
times. The perception that digital technology is more efficient, however, will 
continue to drive costly infrastructural changes at institutions across the country. 
Conclusion 
People have to be convinced that a new intervention, or new way of doing things, 
is better before they will embrace change. The public has been told digital 
mammography improves accuracy of breast cancer screening and has other 
benefits, such as less painful exams and shorter waiting times. On closer 
examination, many of these perceived advantages are neither evidence-based 
nor completely accurate. Nevertheless, the public and many health care 
providers have been eager consumers of the new technology. As digital 
mammography is rolled out across the county it is becoming evident, as stated 
by Dr. Earp, that our perceptions are very real in their consequences. The most 
tangible of these consequences will be investment of precious health care 
resources in digital technology. 
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Diffusion of Innovation 
Our mammographers have not pushed to get to digital. So it's not like they feel 
like, "Oh my gosh, we've got to do this ... " Other than they know, sooner or later, 
we have to do it. 
-- Carl Ravin, MD, Chairman, Department of Radiology, DUMC 
Digital mammography, like other medical technologies before it, has followed 
Everett Rogers' "Diffusion of Innovation" pattern. Rogers' diffusion curve is bell-
shaped, with innovators and early adopters representing the first 16% of the 
population, and laggards at the other tail comprising 16% of the population. The 
middle section, or early and late majorities, make up 68% of the adopting 
population82 Interview respondents have ranged from great digital 
mammography innovators to representatives from the majority who feel that, 
"sooner or later, we have to do it." Although innovators and early adopters are 
necessary for initiating diffusion of innovation, the bulk of actual technology 
distribution is through the early and late majorities. 
Innovators & Early Adopters 
Innovators, who represent 2.5% of the population, are characterized by their 
senses of adventure and fascination with novelty.82· 83 The Principal Investigator 
of DMIST, Dr. Etta Pisano, is a well-recognized innovator at UNC Hospitals. Dr. 
Pisano's eagerness to implement all-digital mammography has been shared by 
her peers. Thus, unlike traditional innovators, Dr. Pisano did not have to "leave 
the village" in order to distribute her ideas. The Hospital's Vice Present for 
Cancer Services believes implementing all-digital mammography was an 
essential component for achieving the Hospital Mission Statement: 
... I think that, if you want to be the best academic, public cancer center in 
the country, you must have this. And so our hope is that all of these 
things will come together and will help us become that, because you know 
our strategic mission is to be "the best academic health care system" ... 
you can't be the "best system" if your premier cancer center doesn't have 
what it needs to be able to service the people with elite care .... 
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In addition to digital mammography's symbolic, theoretical advantages for the 
Cancer Center, UNC also implemented all-digital mammography because of very 
real allegiances. First, UNC Hospitals is proud to be affiliated with Dr. Pisano 
and is interested in spearheading the acceptance of her technology, which has 
perceived potential to revolutionize breast cancer screening. Second, although 
digital infrastructure was very expensive for the hospital, the technology was 
supported by several key members of the budget committee. The VP of Cancer 
Services commented on budget concerns as a rate-limiting step: 
Now, fortunately for us, there are a lot of women in the operations that 
approve this budget. .. including somebody who is a big proponent who 
had breast cancer. .. so we got it through, but it was not easy. 
Early & Late Majorities 
On the national level, digital technology has followed the "curve of adoption" also 
described by Everett Rogers. This curve has an S shape, with a slow early 
phase, a rapid middle phase, and another slow third phase 82· 83 The spread of 
innovation eventually reaches a point, usually between 15% and 20% adoption, 
after which it is difficult to stop further spread. The FDA has kept official counts 
of digital mammography machines in the United States over the past four years: 
Figure 10: National Full-Field Digital Mammography (FFDM) Trends 
14500 ,--·---~----·------···~--, 
' i4000 
!3500 
I 
13000 
2500 
2000 
1500 
1000 
500 
0 
Feb, 
2004 
Feb, 
2005 
Feb, 
2006 
Feb, 
2007 
Feb, 
2008 
l 
oFFDM 
Centers 
•FFDM 
Units 
Source: MQSA National Statistic Archive, FDA Center for Devices and Radiological Health 
54 
This curve illustrates the early to middle phases of technology adoption, as 
described by Rogers. Digital technology grew relatively slowly during 2004 and 
2005, but has grown exponentially from 2006 until 2008. The nation has 
probably surpassed, or will soon surpass, Rogers' benchmark of 15% to 20% 
technology adoption. This low "tipping point" percentage is partially attributable 
to the self-perpetuating, localized nature of technology dispersion among the 
majority. 
Donald Berwick describes the majority as "local in their perspective," and 
"learning about new technologies from people they know."83 Therefore, the 
process of majority adoption began with women asking their individual providers 
for digital mammograms. Providers have generally satisfied these patient 
demands, partially out of self-interests in the potential for digital imaging to 
advance the field of breast imaging. Private digital vendors have also responded 
to growing public demand for digital mammography. These vendors, however, 
have necessarily injected both competition and profitability into the technology's 
dissemination. Finally, because a sufficient majority of women have started 
receiving digital mammograms, the lack of digital mammography among 
underserved populations has become obvious. Thus, advocacy groups are 
beginning to take on the cause of digital mammography, a resource which could 
be more available to underserved populations. 
Patients as Customers 
Media and interview respondents have pointed to patient demand as a local, 
driving force behind the majority's adoption of digital mammography. The first 
women preferring digital mammograms were generally educated, and therefore 
aware of the published, perceived benefits of digital technology. Dr. Earp said 
she experienced a knee-jerk preference for digital mammography, as a promising 
new breast cancer screening tool. Retrospectively, though, she acknowledges 
the lack of evidence for digital mammography among her subpopulation of 
women: 
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I demanded ... I insisted that I have only digital mammograms. From the 
moment when we only had one machine, when I knew the DMIST trial 
was coming out in the New England Journal, I knew Etta had been 
working on it, I knew it was not for me. I knew I was not in a 
subpopulation with dense breasts and younger women and so on .... And 
they would tell me that. And I would say, "Sorry, that's what I'm gonna 
have." And they would say "no" and I would say "yes, yes." And I knew 
individually, I might get some false positives ... but I wanted it. 
This desire to "want it" despite the evidence has also been reflected in media 
accounts. In November 2005, The New York Times quoted one radiologist who 
stated: 
"We have callers who say: 'I simply want the best tool. When can I 
schedule an M.R.I.?' Others say they had their usual mammogram 
screening last month, and it was clear, but now they want a digital 
mammogram, too, 'just in case."'84 
The circulating desire for women to "want the best screening tool" has resulted in 
pressure, at local levels, for implementation of digital systems. Dr. Earp 
described this pressure on the system as "demand from below." Providers and 
third-party payers have responded to the "demand from below" by implementing 
digital systems. 
Providers and Payers Follow Suit 
Many radiologists and breast imaging specialists have been eager to adopt 
digital technology. Some radiologists, however, are more critical recipients of 
digital technology evidence. These late majority or laggard providers have 
conflicting interests in following the evidence, pleasing the "customers," and 
potentially advancing breast cancer screening with digital tools. For example, 
although Duke's Director of Breast Imaging was highly critical of digital 
mammography evidence, he was more nonchalant when he described plans to 
implement the technology: "Do I think it's fine to be all-digital? Sure. If someone 
gave me 6 digital units, would I install them? Yeah." 
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This type of late majority attitude, characterized by "sure's" and "yeah's" rather 
than fervent opinions, has also come to dominate third-party reimbursement 
discussions. Not every Blue Cross- Blue Shield (BCBS) in the United States 
has always agreed to pay for digital mammography. BCBS Michigan initially 
refused to pay for digital mammograms, citing "lack of evidence" for its superiority 
over screen film mammography. The backlash of protests from enrollees, 
advocates and doctors became so fierce that the company changed its policy just 
one month later, and agreed to reimburse for digital at the same rate as 
traditional mammography85· 86 
Interview representatives from BCBS North Carolina similarly recollected "no 
good politics" behind their decision to begin covering digital mammography in 
2002. Rather, the Senior Medical Director of BCBS NC gave the following 
account of the company's decision for reimbursement: 
... the physician community was contacting us and letting us know that 
they were converting to digital mammography ... [inaudible] "How much 
you're going to pay me pay for it?" So, you know, it's been an interesting 
conversation since then ... sitting on the sidelines and watching the 
literature come in ... we ended up kind of jumping out ahead of that, and 
rather than retracting the coverage that we had already committed to ... you 
know, we're a prominent payer with a big target on our backs ... 
BCBS NC's position as a "prominent payer with a big target" on their backs may 
have prompted them to appease patients and health care providers, rather than 
attempting to wait for evidence, as did BCBS Michigan. Both "Blues" were 
sensitive to public pressure. BCBS Michigan and North Carolina reimburse at 
the same rate for digital and screen film mammograms. This is distinctly different 
from the higher Medicare reimbursement for digital. By offering equal 
reimbursements for both modalities, BCBS has satisfied providers seeking 
reimbursement for their digital mammograms and women who think they want 
the technology, but has also made the payments invisible to the company from a 
cost perspective. 
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As digital mammography becomes more prevalent, and women under 50 years 
begin to seek more breast cancer screening, companies like BCBS may be 
pressured to reimburse for digital mammograms at a higher rate than for screen 
film mammograms. The Senior Medical Director of BCBS NC stated such an 
increase in payment would not be financially feasible, given the ambiguous 
benefit of digital screening in breast cancer detection. The Medical Director 
stated: " ... if there was going to be 10 times the benefit from something that was 3 
times the cost, that might be worth it." At this time, it is logical for digital and 
screen film mammography to receive equal reimbursements. As screen film 
mammography is phased out by digital technology, however, it seems likely that 
payments for digital screening will increase significantly among private insurers. 
The Role of the Market 
Several private companies, including General Electric, Hologic, Fuji, Siemens 
and Fischer, have been involved with digital mammography's development and 
marketing. These companies have met the majority's increasing demand for 
digital. The vendors have, of course, been very attentive to suggestions from 
radiologists about improving the technology. The Director of Breast Imaging at 
UNC showed satisfaction with vendor responsiveness when she stated, "the 
different companies, whether they be Fuji, G. E., Hologic ... have really listened to 
the radiologists, who develop their project to help the patient." 
Some policy analysts, however, have been more skeptical about the true 
intentions of vendors and radiologists to "help the patient." The New York Times 
addressed this issue of private market forces influencing health care in a July 
2004 article entitled "Is What's Good for G.E. Good for Health Care?"87 The 
article specifically points to the company's medical technology marketing as a 
leading contributor to "runaway health care costs." Policy analysts indicated 
doctors and hospitals are "eager customers" of medical technology. The 
analysts believed, since insurance companies and other third-party payers have 
"squeezed" reimbursement for traditional office visits, providers must adopt 
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technology for additional revenue generation. Thus, although the collaboration 
between vendors and providers may be partially motivated to "help the patient," 
these two entities also enjoy higher profits from their working relationship. 
Despite the apparent benefits of collaboration between radiologists and 
mammography vendors, many radiologists have also been frustrated with digital 
companies. These frustrations stem from the nature of free market, where 
separate companies have developed slightly different products. Each company 
competes with one another to develop the fastest machines with the clearest 
images. Therefore, digital equipment from several years ago has become 
obsolete in comparison with some of the newer, more efficient and sophisticated 
digital equipment. The Director of Breast Imaging at Duke expressed his 
dissatisfaction with older digital mammography machines, and his hopes for 
newer models: 
... so we've gone with a different vendor for the two additional rooms that 
we're installing because we want something that is robust. And the one 
thing that we've heard about this new vendor is that it's sort of "plug and 
play." We can't afford ... and I don't mean financially, but just headache-
wise, we can't afford the hassles of machines that weren't working on a 
regular basis. 
The Director could, however, encounter another logistical "headache" in his 
decision to purchase equipment from a "different vendor." Unfortunately, 
companies have developed separate machines, which are often incompatible for 
image transfer. This incompatibility between systems has obviously been a 
major barrier for image sharing and telemedicine. Even more concerning, though, 
is that women switching between providers may not have their previous 
mammograms available for comparison. Dr. Pisano addressed this matter in her 
article "Digital Mammography: What's Next?": 
First, the most important recommendation is the group's clear statement 
regarding the desirability of adherence to uniform display standards for 
digital mammography so that all images can be displayed equally well on 
any digital mammography soft-copy system ... To date, vendors have not 
shared these algorithms openly and in fact have treated this all-too-
important feature as a "black box." They tout and sell "upgrades" to their 
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software packages without providing data supporting or justifying the new 
algorithms. Patients and physicians deserve more transparent information 
regarding the utility of new algorithms. 
Several vendors have responded to these concerns by making their equipment 
more compatible for image transference between systems. UNC Hospitals has 
installed a universal mammography display system called "AXA," which allows 
radiologists to install digital mammograms from any company onto the UNC 
PACIS. Not every general radiologist, however, will be able to install these 
universal display systems in their practice. 
Overall, the private market has been responsive to feedback from radiologists in 
the development of digital mammography. At the same time, digital vendors 
have competed with one another to render many systems either obsolete and/or 
incompatible with other systems. Digital companies will probably continue to 
develop their products and make faster, more advanced equipment. Many 
waves of digital mammography re-adoption could wash over the nation as private 
vendors continue to develop technology in a stepwise fashion. 
Equality 
To the extent that Medicare pays for the majority of breast cancer screening, 
mammography is a public good that should be evenly distributed. Digital 
mammography is, however, another resource that is more available to wealthy 
citizens. The first centers to adopt digital mammography also had the richest 
workforces and the most highly specialized physicians. This regional variation of 
digital mammography accentuates health care disparities, as described 
powerfully by Dr. Earp: 
... in the past there was sort of the early adopters, or there were the 
special people, or the people who were close to the decision-makers, or 
those who were in-the-know ... the elites ... but we don't want to wait while 
the elites have theirs! Trends happen first among the elites, and then they 
give it to the poor people and to the ordinary people. 
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Media have also picked up on the inequalities associated with digital 
mammography. Of 215 articles reviewed for this analysis, 39 described the need 
to provide digital technology for uninsured women. Most of these reports have 
been published recently, or between 2005 and present. In October 2007, the 
Chicago Tribune used digital mammography as a poignant example of the city's 
segregated health care system88 The article's data showed hospitals in rich, 
white neighborhoods had significantly more digital mammography units and 
breast imaging specialists than hospitals in poor, minority neighborhoods. 
Breast cancer and other advocacy groups have been among the first to tackle 
this problem of unequal digital mammography distribution. The senior policy 
analyst from the Susan G. Komen Foundation described this role of advocacy 
groups as follows: 
... As digital mammography becomes more commonplace, it's really going 
to be incumbent on advocacy groups like ours and federal and state 
decision makers ... to do some things to ensure that the costs are 
affordable and the technology is available, especially to underserved 
populations. 
Advocacy groups have been very successful in multiple arenas, including policy 
and fund-raising, for installation of digital equipment in underserved areas. The 
Komen Foundation is winning digital mammography funding through the National 
Breast Cancer and Cervical Cancer Early Detection Program (NBCCEDP), which 
provides breast cancer screening for uninsured women who do not qualify for 
Medicaid. The senior policy analyst commented on the Susan G. Komen lobby 
for NBCCEDP funds: 
At the federal level, every year we're going to Congress, to the 
Appropriations Committee, and you know all of our supporters and 
activists are going to their individual members of Congress and asking for 
more money for that program ... On the state level, you know, we're 
working through our affiliates ... because we have 122 affiliates across the 
country who have good, strong relationships with their local governments 
and their state governments. 
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In addition to this enormous political lobby, the media have been publicizing other 
advocacy activities and fund-raising events. Digital mammography vans have 
been particularly popular news items, as the Sacramento Bee (May 2006), New 
York Post (March 2007) and Dallas Morning News (April 2007) have all run 
articles covering recent purchases89-91 All these articles praised mammography 
vans for being able to screen about 5,000 women per year who would not have 
otherwise been screened, either due to their rural location or Jack of health 
insurance. Fund-raisers for digital equipment have included everything from 
luncheons with keynote speakers to Christmas ornament sales, tennis 
tournaments and, of course, races for the cure. 92• 93 The majority of fund-raising 
events were either sponsored by or affiliated with the Susan G. Kamen 
Foundation. 
Although advocacy groups have successfully mobilized resources for digital 
mammography in underserved areas, some question the true need for this type 
of technology in rural medicine. Dr. Earp, an expert in rural breast cancer 
screening patterns, commented: 
... I think by and large rural health care doesn't need more machines, 
higher technology. I think it needs more middle-level practitioners, 
whether they're nurse practitioners or physician assistants or general 
internists. I think that 90% of what goes on between a doctor and a 
patient has everything to do with the history taking and the talking, and 
relatively little to do with the labs and the technology. 
Although others express similar skepticism about the true value of digital 
mammography in underserved areas, these opinions have not slowed the 
momentum of advocacy groups. This is potentially because questioning voices 
have arrived after digital mammography has already been accepted by the 
majority as the new beast cancer screening standard. Also, digital 
mammography equipment provides a very concrete, tangible symbol of advocacy 
group efforts to improve access. 
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Conclusion 
Digital mammography has followed Rogers' "Diffusion of Innovation" pattern. 
The majority's adoption of digital technology, however, has been complicated by 
the imposition of several outside interests on the process. Originally, digital 
mammography was perceived to have several theoretical advantages over 
screen film mammography for both patients and providers. The majority of 
women have come to regard digital mammography as the new standard for 
breast cancer screening, and radiologists have responded to these "demands 
from below." At the same time, many radiologists have capitalized on the 
potential efficiencies and profitability digital mammography could bring to their 
practices. Private vendors, in turn, have competed with one another to make 
digital equipment increasingly sophisticated, requiring costly upgrades. Finally, 
advocacy groups have taken up the cause of digital mammography and launched 
campaigns to make the technology available for everyone. 
At this point, we must take a step back and re-examine the evidence. Digital 
mammography is a technology with uncertain public health benefits; however, 
the hubbub of patient demand, market forces and advocacy groups are all 
heavily engaged with the technology's dissemination. As the majority comes to 
adopt digital technology, it seems likely that the voice of evidence will become 
even more muffled. New digital mammography-related interests will enter into 
the national discussion and use particular pieces of evidence to support their own 
positions. 
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The Shifting Cost Burden 
Is it the right thing to do? Yes. Not everything is designed for profit, and we 
realize that. 
-- Michael DeGennaro, Administrative Director of the Department of Radiology, 
UNC Hospitals 
Cost has been the singular negative aspect of digital screening mammography 
upon which both media accounts and interview respondents have converged. 
Newspaper articles pinpointed cost concerns, as 66 out of 215 articles described 
the drawback of cost in either headlines or opening sentences. For example, the 
Detroit Free Press published an article in June 2003 called "Digital Breast Exam 
Eclipsed by its Cost." The article reported findings of a Michigan health advisory 
board that had concluded the costs of digital technology far outweighed its 
benefits. The article quoted a medicine professor from the University of Michigan 
who said, "We can no longer give everything that works to everybody."94 Also, 
after the DMIST results and initial cost-effectiveness analyses were published, 
the Cleveland Plain Dealer published an article titled "Mammography Going 
Digital: It's More Expensive, but Cost-Effective for Some" (January 2008). The 
reporter noted that although digital mammography would only be appropriate for 
a subgroup of women, the technology "like all other medical screening 
technologies before it, is going digital -whether or not it produces the most cost-
effective images."95 
Interview respondents generally agreed that higher costs are the greatest 
disadvantage of digital screening. Seven out of twelve respondents named cost 
as the most prohibitive aspect of digital mammography, and an additional three 
respondents believed cost to be one of the greatest challenges for digital 
screening. Perhaps the Director of Breast Imaging at Duke, a self-proclaimed 
"purist" who "belongs in academic medicine," described the cost of digital 
technology most directly when he stated: 
They (Medicare) shouldn't reimburse more, and there has certainly been 
some political chatter about ending that. Again, given the ACRIN results, 
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showing overall. .. for all-comers, for everyone who walks in the door for a 
mammogram ... no overall difference in cancer detection between digital 
and analog. Why would they pay more for digital? It doesn't make sense. 
Interview respondents diverged in their own reasoning for the higher digital costs. 
No one, through, has taken personal responsibility to control the price of digital 
mammography. The following are examples of the ways in which patients, health 
care providers, and even health system leaders have inappropriately justified 
and/or dismissed digital mammography costs. 
Cost Considerations at Patient-Provider Level 
Although individual patients and providers have been significant forces behind 
developing and marketing digital mammography, they are not invested in the 
technology's cost-effectiveness for the health care system. The Chairman of 
Radiology at Duke described the insignificance of digital cost to the patient: 
Of course, digital costs more. Not that most people care, because they've 
got insurance. 
Health insurance has essentially detached individual "customers," who act as 
price controls, from the digital mammography market. Many radiologists also 
contextualized digital mammography costs from the perspective of their own, 
individual practices. At the local level, digital mammography is cost-effective. 
One radiologist practicing in Appalachia stated, although digital mammography 
may not be cost-effective for the system, "I didn't lose any money ... the 
government had a differential payment. .. it paid for itself to go ahead and buy the 
digital." Dr. Pisano also emphasized this point, saying the cost-effectiveness 
study by Tosteson and colleagues "was done from the perspective of third-party 
payers rather than the perspective of a practice." 
Cost Considerations at the University Level 
Many breast imaging specialists at tertiary medical centers are also disconnected 
from digital mammography cost considerations. The Director of Breast Imaging 
at Duke commented on digital mammography price as follows: 
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... you would have to ask someone with a finance background. I've seen 
arguments made ... I've never calculated it out myself. One of the 
beauties of academic medicine is I don't have to, someone else can do 
that. .. but that's not my area. 
The Director of Breast Imaging at UNC also acknowledged the disadvantage of 
digital mammography costs, but immediately thereafter emphasized the 
technology's potential for downstream cost savings: 
Um ... the only downside to begin with is that it costs more for the 
equipment. The initial start-up is more ... and obviously the benefit is you 
get rid of the processor, you get rid of the dark room, you get rid of your 
costs for film, you get rid of the costs for your chemicals, you get rid of. .. 
unfortunately, the people who service the processor because you've got 
service contracts, people come out and clean it, make sure they're 
functioning appropriately. You get rid of the problem of having to have 
physical, large amounts of storage for folders and films. You know, you 
get rid of that potential of losing films .... So, the initial start-up costs are 
more ... but downstream, digital I really think pays for itself. 
The Director of Breast Imaging gave eight possibly cost-efficient qualities of 
digital mammography in this response. Hospital financial analysts, however, do 
not expect to collect any savings with digital mammography. Specifically, the 
Administrative Director of Radiology at UNC cited the enormous cost of digital 
image storage, which requires more electronic power than does film storage: 
Conventional mammography, for example, would cost somewhere in the 
$80,000 range ... a digital mammographer is somewhere around $500,000. 
What you save, perhaps, on chemistry and processing is nothing 
compared to storage ... the digital storage costs. 
Overall, university radiologists have felt professionally disengaged from the 
problem of digital costs and have embraced unrealistic optimism about 
downstream digital mammography savings. These perspectives of university 
leaders are problematic because smaller practices often follow academic medical 
centers in technology implementation. This creates a domino effect, and digital 
mammography expenses are eventually passed to the federal government or 
other third-party payers. 
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Cost Considerations at the Health System Level 
On a system-wide level, digital mammography can be contextualized as either 
insignificantly expensive or necessarily expensive. Dr. Pisano, for example, 
contextualized digital mammography costs as another expense in our already 
expensive and complicated health care system: 
You know, people look at technology and say "Oh, that's the reason that 
we spend a lot of money." Well, I challenge you to look at the profits of 
insurance companies versus digital mammography. I assure you, it's a 
drop in the bucket compared to how much is skimmed off in profit. 
Dr. Pisano named other health care expenses as far greater threats to the 
system than digital mammography. Although such concerns are certainly valid, 
her response purposefully drew attention away from the cost-ineffectiveness of 
digital mammography. 
Other interview respondents pointed to the health care system as the reason 
behind digital mammography's higher price. For example, the Administrative 
Director of Radiology at UNC blamed some American health regulators for 
driving higher digital mammography prices: 
... if you look what's happening in Europe, a lot of this technology is going 
more mainstream. They don't have some of the gatekeepers of 
technology there, and as a result the cost model is shifted ... [I am] talking 
about the FDA and perhaps Certificates of Need, which have both been 
cited elsewhere as increasing the cost of digital technology. 
Digital mammography costs have even been dismissed by federal health care 
governing bodies. This is partially attributable to system design, because the 
FDA and Medicare are separate entities. The FDA's Director of Devices and 
Radiological Health, Dr. Schultz, commented about technology cost 
considerations: 
OK, well since you mentioned cost. .. cost is not something that we factor 
into our analysis. You know that. We don't look at cost, we look at safety 
and effectiveness ... and health benefit, but we don't look at cost. So, in 
terms of how many people can avail themselves of a technology because 
of cost issues ... I mean, I'm not saying that that's not a very important 
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question and it's not a very important issue from a health policy standpoint, 
but it's not part of our mandate at FDA. 
Although cost-effectiveness is not part of the "mandate at FDA," Medicare 
certainly considers FDA approval status in their decisions to reimburse for new 
medical interventions. In this arrangement, neither federal entity is completely 
informed about the rationale behind the other's decisions. Furthermore, cost-
effectiveness data are difficult to accrue and use for decision making. Thus, it is 
counterintuitive that our nation's technology approval and technology funding 
bodies are so completely separate. 
Conclusion 
Although both media accounts and interview respondents have recognized the 
problem of cost, digital mammography prices are dismissed at all levels, from 
that of the individual patient to the level of federal regulators. Some respondents 
emphasized the relative cost-effectiveness of digital mammography, from the 
perspectives of individual providers. Other health care leaders have described 
digital mammography cost as an inevitable byproduct of our complex, expensive 
system. Finally, many leaders seem to have adopted the colloquial "it's not my 
problem" stance. These hands-off approaches to cost have resulted in no action 
to ensure that digital mammography, or other future medical technologies, are 
subject to more rigorous cost-effectiveness analyses before they can be 
distributed. 
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Lessons from Digital Mammography 
I tell you, I think the whole point a moot question, because I suspect that within 5 
years, patients will all be getting digital tomosynthesis. And the whole analog 
versus digital question will be obliterated. The difference in sensitivities of digital 
versus analog are probably real but slight ... I suspect that it's going to be a 
quantum leap up to tomosynthesis. 
-- Jay Baker, MD, Director of Breast Imaging, DUMC 
The necessity for evidence-based medicine is more clear than ever before, as 
our health care technologies, therapeutics, and costs continue to escalate. Much 
literature has focused on how to make evidence both accessible and sound, or 
based on measures that are equal, valid, and reliable. Despite fine progress by 
expert and disinterested groups such as the USPSTF, we continue to adopt and 
invest in some medical practices for reasons other than evidence. In the case of 
digital mammography, the evidence has been manipulated and/or forgotten in the 
national arena because of our collective excitement about the technology's 
possible advantages. Between our "war on cancer," the potential for digital 
technology to advance breast imaging, the perceived advantages for women, the 
forces inherent in diffusing innovation, market forces, and the drive for health 
care equality, digital mammography adoption has been a disorganized process. 
Perceptions, rather than facts, have propelled the distribution of this new, 
expensive medical technology with questionable public health benefits. 
The next breast cancer screening technology, which has already been met with 
great enthusiasm by researchers and radiologists, is tomosynthesis. One 
interview respondent described tomosynthesis as "like a CT of the breast," which 
produces three-dimensional images rather than the traditional, two-dimensional 
images from screen film or digital mammography. Seven interview respondents, 
including four radiologists, named tomosynthesis as the next step for breast 
cancer screening. 
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Many of the same interest groups that have propelled the spread of digital 
mammography will also drive our adoption of tomosynthesis. Radiologists are 
already eager for tomosynthesis, as articulated by the Director of Breast Imaging 
at Duke: 
... my hope was that tomosynthesis would be approved faster than it's 
been approved ... and it's just no end of frustration to me that G.E. has 
dragged its feet on getting FDA approval. I'm very thankful that Hologic 
has come along and put a fire under the whole modality ... I know there's a 
lack of data to prove it now ... but I do think that tomosynthesis is going to 
be the way to go. I may be wrong, I haven't totally bought into it, but the 
cases I've seen are pretty compelling. 
This excerpt illustrates the pressure for approval of tomosynthesis by both 
radiologists and private vendors, both inextricably linked to the FDA. As we see, 
this academic medical center Director of Breast Imaging is already voicing strong 
enthusiasm for the technology based on his anecdotal evidence rather than data 
from clinical trials. 
Some of the original perceived benefits of digital mammography have now 
become the projected benefits of tomosynthesis. Specifically, the Chairman of 
Radiology at Duke cited potential for lower recall rates and better images as two 
advantages of tomosynthesis: 
So with the tomosynthesis you're able to look at it, if you want to think, 
slice-by-slice ... But, you know, it may be the new thing ... if some lady gets 
called back from a screening mammogram for a finding, to be able to go 
through the breast. Is it just overlapping of tissue? Is it something real, is 
it really a mass? 
Also like digital mammography, hospital administrators are expecting significant 
costs associated with overhauling the current infrastructure and replacing it with 
tomosynthesis equipment. The Administrative Director of Radiology at UNC 
projects tomosynthesis will be a "big cost in transition." The Director, however, 
immediately qualified that view by adding "some of these machines are being 
sold so that they're capable ... you know, digital with tomosynthesis." 
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Over the coming decade, tomosynthesis is likely to become the next generation 
of breast cancer screening. Although information about the technology is not yet 
prevalent in mainstream media accounts, interview respondents working to 
further tomosynthesis adoption are very optimistic about its potential. Before the 
entry of tomosynthesis into the health care market, though, we must 
dispassionately evaluate its true advantages from a public health perspective. 
Such an evaluation could take place through a federally-supported program to 
regulate new medical technologies. Dr. Earp described such an agency as a 
"whistle-blower" who would need "federal legislation to protect them because, 
almost inevitably, there's a movement to wipe them out." The Institute of 
Medicine recently called for a new, single program with "authority, overarching 
responsibility, sustained resources, and adequate capacity to ensure production 
of credible, unbiased information about what is known and not known about 
clinical effectiveness."96 Although the creation of this program could help 
clinicians practice evidence-based medicine, I believe the proposal should be 
expanded. 
We need one federal regulatory program mandated to evaluate medical evidence, 
and then approve and/or assign funding for new medical technologies based on 
evidence appraisal, perhaps similar to the National Institute for Clinical 
Effectiveness in the United Kingdom. Evaluators would necessarily include elites 
in the fields of medicine, technology and finance. These people would 
collaborate to consider the relative effectiveness, harms, and costs of every new, 
proposed medical intervention. The program could feasibly be created from an 
existing bureaucracy such as the USPSTF, the FDA (for which this role had 
already been discussed in Congress during debate over the latest reauthorization 
of the Prescription Drug User Fee Act and the Medical Device User Fee and 
Modernization Act [PL 11 0-85]) , or even the Centers for Medicare & Medicaid 
Services. These organizations would require some redefinition of their 
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Congressional mandates in order to become more influential gatekeepers of 
medical technologies. 
The program would require tremendous resources to function effectively, but 
could eliminate many of the apparent miscommunications between federal 
programs that presently allow ambiguously effective technologies, such as digital 
mammography, to become standards of care. For example, having one 
regulatory program responsible for appraising medical literature and approving 
new technologies could reduce the uncertainty in many of the FDA's decisions, 
which are based on limited "safety and effectiveness" data. Furthermore, 
connecting the technology approval process with decisions about funding would 
allow more effective technologies to be more generously reimbursed. Over the 
long term, such a centralized program could help contain health care costs by 
ensuring that only effective medial interventions enter the health care market and 
receive Medicare/Medicaid reimbursement. 
The main threats to this proposed health regulatory program are inefficiency and 
potential for political manipulation. Both these threats may be resisted by 
assuring the program has sufficient autonomy and resources to maintain 
efficiency and integrity against partisan interests. Also, in terms of efficiency, 
creating such a program would necessarily invoke a paradigm shift among 
technology patrons, such as those of digital mammography, who were eager for 
product approval and funding despite limited evidence. These patrons must 
come to understand the importance of having clinical trials prior to approving new 
medical technologies for mainstream use. Thus, the program could potentially, 
and in many cases appropriately, further delay approval of many new 
technologies. 
The ability ofhealth care researchers and providers to develop complex 
technologies, such as digital mammography and tomosynthesis, is one of the 
greatest attributes of our health care system. Our propensity to improve 
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technology and reward innovation has enabled clinicians to share information, 
enhance patient quality of life, and improve survival times. At the same time, 
however, it is important to balance acceptance of new technology with shrewd 
appraisal of the evidence. Achieving this balance will continue to be an 
extremely difficult, although absolutely necessary, component of fixing our health 
care system. 
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Appendix 1: Coding Summary of Interview Responses 
#War terms used: Number of times respondent mentioned the words "fighter," "war," and/or 
"save lives" during the encounter. 
Subjective experience, Radiation Dose. Recall Rates: Four radiologists commented on these 
parameters during the interviews. Subjective patient experience refers to the painfulness and 
length of study for digital versus screen film mammography. Radiation dose refers amount of 
radiation delivered to patients during digital versus film mammography. Recall rate refers to the 
volume of patients requiring further work-up after digital versus screen film examinations. 
Cost disadvantage: All interview respondents except one discussed digital mammography costs. 
Respondents either indicated cost was the "greatest" disadvantage of the technology, 
acknowledged cost as one disadvantage ("yes"), or did not acknowledge cost as a disadvantage 
("no"). 
Tomosynthesis: Interview respondents who cited screening tomosynthesis as the most promising 
future avenue for breast cancer screening. 
Respondent #War Subjective Less Less Cost Tomosynthesis: 
Terms Experience Radiation? Recall? Disadvantage Next Step? 
Used Different? (YiN) (Y/N) 
(YiN) 
Matthew 2 N/A N/A N/A Greatest -
Moore 
Cherie 1 No No No Yes Yes 
Kuzmiak, 
MD 
JoAnne 5 N/A N/A N/A Greatest Yes 
Earp, SeD 
Carl Ravin, 1 No No No Greatest Yes 
MD 
Jay Baker, 0 No No No Yes Yes 
MD 
Marlene 3 N/A N/A N/A Greatest Yes 
Rifkin 
Michael 0 N/A N/A N/A Greatest Yes 
DeGennaro 
Daniel 0 N/A N/A N/A Yes -
Schultz, MD 
Mills Antley, 0 N/A N/A N/A No -
Jr, MD 
Etta Pisano, 3 No No No Yes Yes 
MD 
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Eugenie 0 N/A N/A N/A Greatest -
Komivies, 
MD 
Jackie 0 N/A N/A N/A - -
Wynn, RN 
81 
Appendix 2: Coding Summary of Media Review 
***War language: 
Of 215 digital mammography articles analyzed, 44 used the following war-related terms in either 
their titles or opening paragraphs: weapon, war, struggle, fight. The following are only articles 
that used war-related terms in their titles. 
Headline Outlet Date 
Using Defense Know-How for Health Care- Technology to Washington Post 2-Jul-04 
Hunt Warheads May One Day Find Tumors 
Defense technology may be used to help detect breast Wall Street Journal 12-0ct-94 
cancer 
Crowd for a cure --Thousands join the fun to fight breast The Sacramento 14-May-06 
cancer Bee 
U.S. Weapons Lab, Firm Unite in War Against Breast The Sacramento 7-0ct-93 
Cancer-- Lawrence Livermore Partnership Aims For Better Bee 
X-Ray Device 
Breast-cancer detection may employ 'star wars' technology- Orange County 28-Nov-93 
MEDICINE: A digital mammography machine could provide Register 
sharply improved images of early cancerous tissue 
Breast cancer fight hopeful, frustrating Houston Chronicle 19-May-02 
Weapon in war against cancer/Spy technology will soon be Houston Chronicle 5-Apr-95 
trained on breast tumors 
Spies In The Sky VS. Breast Cancer High-Tech Wizards New York Daily 31-0ct-99 
Spotting Tumors Missed By Doctors News 
Foundation keeps word to a friend -- $5 million donation to Chicago Tribune 2-0ct-98 
fight breast cancer sets record for area 
Scientists enlist Star Wars tech in battle against breast Chicago Tribune 28-Nov-93 
cancer 
Digital detection -- Make full use of new weapon against Detroit Free Press 20-Sep-05 
breast cancer 
The move: From bombs to breast cancer aid Detroit Free Press 31-0ct-97 
NASA high tech may help fight breast cancer Detroit Free Press 18-0ct-94 
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Missiles to Mammograms: New Uses for Technology Plain Dealer, The 18-Aug-97 
(Cleveland) 
Health Watch - Helping to fight breast cancer- Military Atlanta Journal- 12-Apr-95 
equipment, other high-tech tools may aid in detection Constitution, The 
CIA offers computer-image technique to aid in early breast- Dallas Morning 5-Apr-95 
cancer Military target finder may help save women News, The 
Space, defense technology being used to fight breast Star-Ledger, The 17-Aug-97 
cancer 
Hillary Clinton hurts the fight on breast cancer Newsday 4-Apr-00 
Star Wars Secrets Yield Weapon for Breast Cancer Newsday 19-Dec-95 
From Sword to Scalpel Partners develop breast cancer Newsday 2-Jun-94 
detector 
***Digital cameras/word processors as vehicles to explain digital mammography: 
Articles that explained digital technology using the metaphor of cameras and/or word processors: 
Total # of articles (A) Articles explaining (B) Articles mentioning B/A *(1 00) 
digital mechanics digital camera or word 
processor in explanation 
215 31 20 64.5% 
***Articles explaining DMIST: 
Analysis of the tones of titles/opening sentences of newspaper articles explaining results of the 
DMIST. 
Total articles: 21 
Total negative articles: 1 
Total positive articles: 1 0 
Total neutral articles: 10 
Other digital advantages 
Headline Outlet Date Tone mentioned? 
Finding More Cancer Washington Post 10-Apr-07 Neg y 
Isn't the Answer 
heart disease High Washington Post 27-Sep-05 Neu y 
blood sug .... 
Digital Mammograms Washington Post 17-Sep-05 Pos y 
Find More Cancers 
Digital imaging improves USA Today 16-Sep-05 Neu y 
mammograms before 50 
Digital mammograms USA Today 19-Sep-05 Neu y 
are better, but scarce 
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Digital Mammograms Wall Street 17-Sep-05 Pos y 
Excel in Study Journal 
Are Mammograms Right NYT 1-Nov-05 Neu y 
for Everyone? 
Study Weighs The Two NYT 17-Sep-05 Neu y 
Types of Mammogram 
Technology targets Houston 26-Jan-06 Neu y 
breast cancer - Chronicle 
Research, technology Houston 20-0ct-05 Pos y 
improve breast cancer Chronicle 
treatments - Gene 
essays, digital imaging, 
aid in detection 
Digital mammograms Houston 17-Sep-05 Pos y 
spot cancer better, study Chronicle 
finds 
Digital screening for Chicago Tribune 17-Sep-05 Neu y 
breast cancer gets 
mixed review- More 
accurate for young, but 
not overall 
Latest reseach, new Detroit Free 22-0ct-06 Neu y 
tests Press 
Breast cancer Detroit Free 23-May-06 Neu y 
awareness during 5 Press 
years, cost of 
mammograms has 
steadily risen in state 
Digital detection -- Make Detroit Free 20-Sep-05 Pos y 
full use of new weapon Press 
against breast cancer 
Proofs in on digital Detroit Free 17-Sep-05 Pos y 
breast test: it's better Press 
The power of detection Newsday 17-Sep-05 Pos y 
Study gives digital 
mammography the 
advantage in spotting 
cancer in women 
younger than age 50 
Researchers call breast Boston Globe, 12-Feb-07 Neu y 
density a cancer risk too The 
long ignored 
Study sees new hope Star -Ledger, The 17-Sep-05 Pos y 
for finding breast cancer 
Image is everything Star-Ledger, The 17-0ct-05 Pos y 
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Digital mammograms San Francisco 17-Sep-05 Pas y 
found better for younger Chronicle 
women 
***Reduced pain and/or radiation: 
Out of 215 media articles reviewed for this analysis, 38 mentioned digital mammography's ability 
to reduce pain and/or radiation exposure. The following are some examples of articles that 
addressed pain and/or radiation exposure in their titles or leading paragraphs. Note the 
references to less pain and/or radiation are in bold: 
Headline Outlet Date Key Excerpt 
Remodel mammography? It Chicago 4-0ct-98 Women forever dreading what some call the 
couldn't hurt Tribune "slam-o-gram" may find some relief in the 
future, or at least more reliable results than in the 
past, thanks to two developing techniques. 
Women get a new mammogram Detroit 17-Jan-01 Digital mammography-- a computerized X ray--
option digital x rays are faster Free Press cuts in half the approximately 15-20 minutes 
and more comfortable usually needed to perform mammography. That 
means women don't have to stand as long 
with their breast compressed tightly between 
heavy plastic devices -- a common complaint 
among women that some say deters them 
from getting mammograms. 
Imaging and other cutting-edge Chicago 30-Nov-98 After decades of relying on X-rays and film to 
technologies in hopes of Tribune detect breast cancer, physicians are working to 
improving the early detection of create a new world of high-technology 
breast cancer while at the same mammography that promises less painful 
time reducing the need for testing, fewer false readings and a smaller 
women to have biopsies. necessity for biopsies. 
Research, technology improve Houston 20-0ct-05 Radiologist Dr. Larry Grissom of Houston 
breast cancer treatments - Gene Chronicle Northwest Medical Center has been using digital 
essays, digital imaging, aid in mammograms since 2002. Grissom said the 
detection advantage of digital mammograms can be 
likened to computer-based digital photo 
programs .... "And the amount of dosage with 
digital is up to one third less because you 
manipulate the image instead of having to 
repeat the mammogram." 
New Digital X-Rays Offer a Wall Street 3-Mar-00 The digital mammogram is just one of a slew of 
Clear Picture That Patients Also Journal new digital X-ray technologies slowly appearing 
See in hospitals and dentists' offices around the 
country .... But doctors and radiologists say the 
digital X-rays offer benefits, including time 
savings, better visibility for the person reviewing 
the X-ray and, in some cases, less radiation 
exposure. 
***Inequality: 
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Of the 215 articles reviewed, 39 described unequal distribution and/or the need to provide digital 
technology for the uninsured. The following are some examples of articles that address inequality 
through their titles (chronological order): 
Headline Outlet Date 
Race For The cure a sorority of survivors Houston 30-Sep-99 
Chronicle 
Mammograms called best option - Review backs Dallas Morning 9-Mar-01 
more research, better access for the uninsured News, The 
X-ray van stays in S.F. San Francisco 16-Dec-01 
Chronicle 
Elmhurst Gets 550G for Mammogram Van New York Daily 31-Mar-04 
News 
Tennis tourney a cancer fund-raiser Atlanta Journal- 8-May-04 
Constitution, The 
Rell's Treatment Highlights Hurdles For NYT 9-Jan-05 
Screenings Faced by Many 
Digital mammograms are better, but scarce USA Today 19-Sep-05 
Crowd for a cure-- Thousands join the fun to fight The Sacramento 14-May-06 
breast cancer Bee 
Tears of joy for the mammogram van- Hospitals Dallas Morning 10-Apr-07 
take testing to underserved communities News, The 
Local Hero- Bringing Vital Cancer Detection to the New York Post 21-Mar-07 
Streets 
More Mammograms NYT 20-May-07 
Breast cancer panel decries city's 'segregated' Chicago Tribune 18-0ct-07 
system 
***Cost as Disadvantage: 
Newspaper articles pinpointed cost concerns, as 66 out of 215 articles described the drawback of 
cost either through their titles or opening sentences. The following are only those articles that 
addressed cost concerns through their titles: 
Headline Outlet Date 
Breast cancer awareness during 5 years, cost of Detroit Free Press 23-May-06 
mammograms has steadily risen in state 
Cancer test costs rise as waits fall -- reimbursement Detroit Free Press 17-Jun-03 
rates lag at many of state's mammography centers 
Digital breast exam eclipsed by its cost Detroit Free Press 7-Jun-03 
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Mammography going digital: It's more expensive, but Plain Dealer, The 1-Jan-08 
cost-effective for some (Cleveland) 
Health Costs Underestimated, Experts Say NYT 30-Nov-00 
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Appendix 3: Digital Mammography Interview Questions 
Please note 3 different interview formats for participants, based on their participation in 
affiliation with UNC, Duke, or other women's health organizations. 
UNC Hospitals: 
In your opinion, what were the most important factors leading to UNC's adoption of 
digital mammography in September, 2007? 
What types of issues arose in switching from plain film to digital? What were the 
debates and struggles that had to be settled before the switch? Have any new, 
unforeseen issues with cost, quality, or logistics arisen since the transition? 
How has infrastructure had to change during the switch from plain film to digital 
mammography? What has been required of radiologists and technicians? What were 
the costs? What was sacrificed in order for UNC to make the switch? 
Now that we have implemented digital mammography as standard of care at UNC, how 
do you think we should measure the successes and shortcomings of digital 
mammography in the future? What is your hope for digital mammography? 
Dr. Pisano's 2005 "Diagnostic Performance of Digital versus Film Mammography for 
Breast-Cancer Screening" in the NEJM DMIST Trial emphasizes the superior diagnostic 
accuracy of digital mammography in detecting breast abnormalities in women under 
50yo and pre-/peri-menopausal women. At the same time, the literature shows digital 
and plain film mammography to be roughly equivalent in their diagnostic accuracy for the 
majority of women we currently screen (age 50+). What are your thoughts on how digital 
mammography will affect breast cancer screening? 
In deciding to convert to digital mammography, did UNC consider what the switch would 
mean for the rest of the state? {What do you mean? Did you think about what would 
happen in the rest of the state as a result of UNC going completely digital?} 
In your opinion, how has digital mammography been received by patients, physicians, 
technicians, and support staff at UNC? 
Digital mammograms are much more expensive than are plain film mammograms. 
{Give the$ value} Could you give me your opinion on how a cost-effectiveness 
argument can -or can't- be made on behalf of digital mammography? 
Questions for Radiologists: 
In your opinion, how will the switch to digital mammography affect quality? 
Some radiologists feel that digital mammography will increase potential for image 
sharing and therefore increase breast imaging accuracy. What are your opinions on 
this? Will digital mammography relieve some of the litigious burden of reading 
mammograms? 
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What types of challenges are associated with comparing old plain film mammograms 
with new digital images? 
Duke University Medical Center: 
In your opinion, what is the current role of digital mammography at DUMC? 
The literature shows digital and plain film mammography to be roughly equivalent in their 
diagnostic accuracy for the majority of women we currently screen (age 50+). However, 
digital mammography has proven superior to plain film in breast imaging for women 
aged 40-50 and pre/peri-menopausal women. What are your thoughts on how digital 
mammography might affect breast cancer screening? 
Would you say that DUMC paid any attention to UNC's recent transition from plain film to 
digital mammography for breast imaging and screening for breast cancer? In your 
opinion, is it the right time to transition from plain film to digital? What would or would 
not have to happen for a similar transition to happen at DUMC? 
Medicare reimburses -90 dollars for plain film and -150 for digital mammography. At 
the same time, the new equipment and training to capture/interpret digital 
mammography are tremendously expensive. How do you think cost factors will 
influence the decision the switch from plain film to digital mammography, both in the 
academic and private sectors? 
Some public health officials have expressed concern that transitioning from plain film to 
digital mammography is a "slippery slope" which creates an atmosphere where more 
expensive screening tools, such as MRI, will become more commonplace. What is your 
opinion on this? 
In your opinion, what should the future hold for digital mammography at DUMC? 
Questions for Radiologists 
Many radiologists have been very enthusiastic about the potential of digital 
mammography. Many believe advancements in technology could eventually make 
digital far superior to plain film. What are your thoughts about this? What are the 
potential diagnostic advantages of digital mammography? 
Some radiologists feel that digital mammography will increase potential for image 
sharing and therefore increase breast imaging accuracy .. What are your opinions on 
this? Will digital mammography relieve some of the litigious burden of reading 
mammograms? 
Other Leaders/Experts in Breast Cancer Screening: 
In your opinion, how well are we doing with breast cancer screening in general? 
Is everyone who needs to be screened getting screened? 
Are some people, who don't need to be screened, getting screened? 
What have been the greatest successes in breast cancer screening with our 
current technology? 
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What are the biggest challenges within our current breast cancer screening 
method? 
Several large, tertiary care centers, including UNC Hospitals, have transitioned 
completely from plain film to digital mammograms for breast cancer screening. What are 
your feelings about digital mammography? 
Do you think it's reasonable for digital mammography to become the new standard 
screening method for breast cancer, nationwide? Is it the right time? 
How do you think we should measure the successes and shortcomings of new methods 
of breast cancer screening, especially digital mammography, in the future? 
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Appendix 4: Interview Respondents and Positions 
Respondent Position Interview Interview Location Interview 
Date Lenqth 
Matthew Moore Senior Policy Analyst at 3/24/08 Phone call to 20 minutes 
Susan G. Kamen Dallas, TX 
Foundation 
Cherie Director of Breast 3/24/08 Phone call to 33 minutes 
Kuzmiak, MD Imaging at UNC Chapel Hill, NC 
Hospitals 
JoAnne Earp, Medical Sociology, 3/28/08 Chapel Hill, NC 45 minutes 
SeD Breast Cancer 
Screening Patterns 
Expert, Patient 
Advocate 
Carl Ravin, MD Chair, Department of 3/31/08 Durham, NC 25 minutes 
Radiology, Duke 
University Medical 
Center 
Jay Baker, MD Director of Breast 4/1/08 Durham, NC 45 minutes 
Imaging, Duke 
University Medical 
Center 
Marlene Rifkin Senior Vice President, 4/4/08 Chapel Hill, NC 35 minutes 
Women's and Children's 
Hospitals and Cancer 
Services, UNC Hospitals 
Michael Administrative Director 4/4/08 Chapel Hill, NC 35 minutes 
DeGennaro of UNC Radiology 
Department 
Daniel Schultz, Director of FDA Center 4/10/08 Phone Call to 23 minutes 
MD for Devices and Washington, DC 
Radiological Health 
Mills Antley, Jr, Blue Ridge Radiology, 4/10/08 Phone Call to 10 minutes 
MD General Radiologist Morganton, NC 
Etta Pisano, PI, DMIST 4/14/08 Chapel Hill, NC 30 minutes 
MD 
Eugenie Vice President/Senior 4/14/08 Chapel Hill, NC 30 minutes 
Komivies, MD Medical Director of 
BCBS NC 
Jackie Wynn, Director of Medical and 4/14/08 Chapel Hill, NC 30 minutes 
RN Reimbursement Policy 
ofBCBS NC 
*I conducted all 1nterv1ews m person except for those w1th the FDA Director, the Director of breast 
imaging at UNC, the senior policy analyst from the Susan G. Komen Foundation, and Dr. Mills 
Antley, whom I interviewed by telephone. 
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1 USA Today 
Appendix 5: Top 25 Circulating Newspapers 
Rated by A. C. Nielsen in Spring 2007 
2 The Wall Street Journal 
3 New York Times 
4 LA Times 
5 New York Post 
6 New York Daily News 
7 Washington Post 
8 Chicago Tribune 
9 Houston Chronicle 
10 Arizona Republic 
11 Dallas Morning News 
12 Newsday (Long Island) 
13 San Francisco Chronicle 
14 Boston Globe 
15 Star-Ledger of Newark 
16 Atlanta Journal Constitution 
17 Philadelphia Inquirer 
18 Star Tribune of Minneapolis 
19 Cleveland Plain Dealer 
20 Detroit Free Press 
21 St. Petersburg Times 
23 San Diego Union-Tribune 
24 Orange County Register 
25 Sacramento Bee 
*I reviewed all available articles published after 1990, but several newspaper electronic archives 
were not accessible from this early date. Thus, I reviewed The Cleveland Plain Dealer from 1991, 
The Star-Ledger of Newark from 1996, The Arizona Republic from 1999, The NY Daily News 
from 2000, TheN. Y. Post from 1999, The L.A. Times from 1996, and The N.Y. Times from 1995. 
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